Document:

Exhibit 10.5

 

NON-EXCLUSIVE LICENSE AGREEMENT

This Agreement is made effective as of the date of the last to sign party on page 15 (“Effective Date”), by and between the Wisconsin Alumni Research Foundation (“WARF”), a nonprofit Wisconsin corporation, and Asterias Biotherapeutics Incorporated (“Asterias”), a corporation organized and existing under the laws of Delaware, and its Affiliates who agree to sign on and be bound by the terms and obligations of this Agreement (collectively, “Licensee”). To the extent any Affiliate exercises any rights granted to Licensee hereunder, Asterias is liable to WARF for the duties and obligations of any such Affiliate, and any act or omission of an Affiliate that constitutes a breach of this Agreement shall be deemed to be a breach by Asterias.

WHEREAS, WARF owns or holds certain intellectual property rights to the inventions described in the Licensed Patents defined below; and

WHEREAS, Asterias (previously known as BioTime Acquisition Corporation) and its Affiliate BioTime, Inc. (“BioTime”) entered into an Asset Contribution Agreement dated January 4, 2013 with Geron Corporation (“Geron”), pursuant to which certain patents, know-how, documents, materials, and other assets relating to Geron’s embryonic stem cell programs will be contributed to Asterias (the “ACA”); and

WHEREAS, WARF previously granted to BioTime, a non-exclusive license under certain Licensed Patents, Licensed Materials, and Wisconsin Materials in certain fields covering certain products as provided therein, i.e., Agreement No. 08-0155, and amendments, (the “BioTime Research License”); and

WHEREAS, WARF and BioTime wish to maintain the BioTime Research License, and Licensee desires to obtain a license under the Licensed Patents, Licensed Materials and Wisconsin Materials for Internal Research (defined below) and to make, use and sell Products in the Licensed Field (all defined below) and WARF is willing to grant to Licensee such a license under the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, the parties covenant and agree as follows:

Section 1.                      Definitions.

For the purposes of this Agreement, the Appendix A definitions shall apply.

Section 2.                      Grant.

A.                  License.

(i)            Subject to the terms of Section 2B, WARF hereby grants Licensee a world-wide, nonexclusive license (a) under the Licensed Patents to make, use and receive Licensed Materials, and (b) under WARF’s rights in the Wisconsin Materials to make, use and receive Wisconsin Materials; in each case, solely for use in Internal Research.

(ii)            Subject to the terms of Section 2B, WARF hereby grants Licensee a world-wide, nonexclusive license (a) under the Licensed Patents to make, use and receive Licensed Materials, and (b) under WARF’s rights in the Wisconsin Materials to make, use and receive Wisconsin Materials; in each case to develop, make, have made, use, distribute, sell, import, and offer for sale Products in the Licensed Field and Licensed Territory; for clarity, Licensee may not distribute, sell or offer for sale any Wisconsin Materials, but may distribute, sell or offer for sale Products that are Derivative Materials.

Page 1 of 23

B.                   Restrictions and Limitations.

The licenses granted under this Agreement do not provide any right or license to: (i) grant any sublicenses under this Agreement to any third parties other than as expressly provided for below; or (ii) use the Licensed Patents, Wisconsin Materials or any Derivative Materials in the manufacture or distribution of Products for any commercial purpose or in human clinical trials in fields outside the Licensed Field.

C.                   Sublicensing.

(i)                  Licensee may grant written sublicenses to third parties under the nonexclusive licenses granted herein in the Licensed Field, but only:

(a)            To Contract Services Providers to enable the Contract Service Provider to perform specific services solely for Licensee’s benefit in support of Licensee’s development or commercialization of Products, under a written contract with Licensee, at Licensee’s expense, and pursuant to protocols or specifications developed by Licensee.  Such a sublicense may include a license to make or use Licensed Materials, Wisconsin Materials or Derivative Materials, or Products, solely for the purpose of providing the services to Licensee, or to sell Products as Licensee’s agent, but not to sell or transfer any of them for any other purpose, or to or for any other entity, and shall state the Licensed Materials, Wisconsin Materials and Derivative Materials must be destroyed within thirty (30) days of the completion or termination of the services.  Licensee will not receive from any Contract Services Provider any payments or any non-cash consideration in exchange for the grant of a sublicense hereunder and any Products sold by Contract Services Providers as Licensee’s agent will be treated as Products sold by Licensee under this Agreement.

(b)            To Collaborators to enable the Collaborator to engage in a project of collaborative research with Licensee on (i) the Licensed Materials or Wisconsin Materials, and cells derived from such Licensed Materials or Wisconsin Materials, and/or (ii) the development of Products, provided that the project is described and directed by a Collaborative Research Agreement including a specific workplan collaboratively established by Collaborator and Licensee and that Licensee has the first right to any data and IP arising from such Collaboration.  Such a sublicense may include a license to make or use the Licensed Materials, Wisconsin Materials or Derivative Materials, or Products, solely for the purpose of carrying out its obligations under the collaborative research project, but not to sell or transfer any of them for any purpose and shall state the Licensed Materials, Wisconsin Materials and Derivative Materials, and any Products, must be destroyed within thirty (30) days of the completion or termination of the project.  Licensee will not receive from any Collaborator any payments or any non-cash consideration in exchange for the grant of a sublicense hereunder.

Page 2 of 23

(c)            To Development Partners to enable the Development Partner to develop or commercialize Products initially substantially developed by Licensee, provided WARF does not disapprove as provided below.  In the event that such sublicense includes a grant of a limited commercial sublicense to a Development Partner: (i) a copy of such sublicense shall be provided to WARF for review at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] business days prior to execution, (ii) such sublicense shall specifically identify the Products covered by such commercial sublicense and shall only include rights under Licensed Patents and Wisconsin Materials as reasonably necessary in the development of those Products, (iii) Licensee, an Affiliate or Geron Corporation (“Geron”) must have previously invested at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] in the development of each Product to which the sublicense applies, and (iv) Licensee shall remain directly responsible for paying to WARF the consideration described in Sections 4B, 4C and 4F that are incurred (and/or received) as a result of such sublicense and/or Development Partner’s subsequent development and commercialization of such Products under such sublicense.  Such a sublicense may include a license to make, use and receive the Licensed Materials, Wisconsin Materials or Derivative Materials, and to develop, make, have made, use, distribute, sell, import and offer for sale Products, in each case solely to the extent permitted by this Section 2C(i)(c), and shall state the Licensed Materials, Wisconsin Materials, and Derivative Materials, and any Products, must be destroyed within thirty (30) days of the expiration or termination of the sublicense agreement.  WARF shall have the right to disapprove of a commercial sublicense with a Development Partner only if it reasonably believes that Licensee, Affiliates, or Geron have not previously invested at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] in the development of the Product that is the subject of such sublicense, or that the rights extended under such sublicense are not reasonably necessary for the development or commercialization of the licensed Product.  If WARF does not inform Licensee in writing of its disapproval and the reasons for it within fifteen (15) business days after Licensee informs WARF of the proposed terms, WARF shall be deemed to have approved them.  For sake of clarity, no right or license may be extended to a Development Partner to research, develop and/or commercialize any Product that was not initially substantially developed by Licensee, an Affiliate or Geron.  Licensee will not receive from any Development Partner any payments or any non-cash consideration in exchange for the grant of a sublicense hereunder that is not fully accounted for under this Section 2C and Section 4C below.

(d)        To Corning Incorporated to enable Corning to sell surfaces, glassware and plasticware for the growth of pluripotent stem cells (“Corning Surfaces”) developed and tested by Corning under the Collaboration and License Agreement between Corning and Geron, effective as of June 15, 2006, amended and restated as of August 24, 2012, which will be assigned to Licensee as of closure of the Asset Contribution Agreement between Licensee and Geron (the “Corning Collaboration and License Agreement”).  Such sublicense: (i) shall be solely for the performance of Corning’s activities under the Corning Collaboration and License Agreement, and (ii) shall not include any right to transfer a sublicense under the Licensed Patents to Corning customers with the purchase of Corning Surfaces.  In consideration of the rights granted herein, Licensee agrees to pay to WARF [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of all consideration (actual and in kind) received by Licensee from Corning that is the result of or covers any invention made as a part of the Development Partnership Agreement (including without limitation up-front license fees, annual license maintenance fees, milestone payments, royalty payments, equity ,and share of profits, but excluding any payments received to fund research under the development partnership).  Such percentage shall be reduced to [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] if the consideration received from Corning and to be paid to WARF was also paid by Corning in exchange for a sublicense to other intellectual property owned or controlled by Licensee required for the purposes of the development partnership.  In both cases, such payment shall continue until such time as none of the sublicensed Licensed Patents remains enforceable, unless this Agreement is terminated earlier as provided herein.

Page 3 of 23

(ii)                Any agreement granting a sublicense under this Section 2C shall contain terms and conditions no less restrictive than those set forth in this Agreement, and state that the sublicense is subject to the termination of this Agreement; that further sublicensing is prohibited; that the sublicensee is not authorized to transfer any Licensed Materials, Derivative Materials or Wisconsin Materials, or Products, or use them for any purpose outside that permitted by the sublicense; and that the sublicensee will not use Licensed Materials, Derivative Materials or Wisconsin Materials to perform any of the following experiments: (a) intermixing of Licensed Materials, Derivative Materials or Wisconsin Materials with an intact embryo, either human or nonhuman; (b) implanting Licensed Materials, Derivative Materials or Wisconsin Materials, or products of Licensed Materials, Derivative Materials or Wisconsin Materials, in a uterus; or (c) attempting to make whole embryos by any method.  Licensee shall require that its sublicensee(s) comply with all requirements, restrictions, limitations and obligations, and acknowledge all limitations of warranties provided in this Agreement, including without limitation those in Sections 2C, 5-7, and 12-15, of this Agreement (to the extent applicable to the work under the sublicense) and Licensee shall have responsibility for the performance of any sublicensee under such sublicense.  Licensee shall provide to WARF, in confidence, a summary of any sublicense agreement under this Section 2C within thirty (30) days after execution of such sublicense agreement subject to the obligation, however, in the case of commercial sublicenses to Development Partners to have earlier provided the proposed terms as required above in Section 2C(i)(c).

D.                 License to WARF.

Licensee hereby grants, and shall require its sublicensee(s) to grant, to WARF a world-wide, nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant sublicenses, to the University of Wisconsin, the WiCell Research Institute and the Morgridge Institute for Research, to make, have made, use and otherwise practice Developments for Non-Commercial Research Purposes.

Section 3.                      Reporting.

A.                  Within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the Effective Date of this Agreement, Licensee shall submit to WARF a Development Plan describing its intended development efforts relating to Products.  If WARF does not inform Licensee of its disapproval of such Development Plan within thirty (30) days, the Development Plan shall be deemed accepted and shall be incorporated hereto as Appendix E. The Development Plan shall include a timeline indicating Licensee’s internal operating estimate of when Licensee will [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]. Licensee shall diligently develop, manufacture, market and sell Products in the Licensed Field throughout the term of this Agreement.  Such activities shall include, without limitation, those activities listed in the “Development Plan”.  Licensee agrees that it shall take all commercially reasonable steps to meet the development program as set forth therein.

 

B.                  Beginning in June 2014 and until the Date of First Commercial Sale, Licensee shall provide WARF with a semi-annual written Development Report summarizing Licensee’s (and those of its sublicensee(s)’) development activities since the last Development Report and any necessary adjustments to the Development Plan.  Licensee agrees to provide each Development Report to WARF on or before [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] from the end of each semi-annual period ending June 30 and December 31 for which a report is due, and shall set forth in each Development Report sufficient detail to enable WARF to ascertain Licensee’s progress toward the requirements of the Development Plan. WARF reserves the right to audit Licensee’s and its sublicensee(s)’s records relating to the development activities required hereunder.  Such record keeping and audit procedures shall be subject to the procedures and restrictions set forth in Section 6 for auditing the financial records of Licensee.

Page 4 of 23

C.                  Licensee acknowledges that any failure by Licensee to make commercially reasonable efforts to develop, manufacture, market and sell Products, or to make timely submission to WARF of any Development Report, or the providing of any false information to WARF regarding Licensee’s development activities hereunder, shall be a material breach of the terms of this Agreement, subject to the right to cure under Section 7.

Section 4.                      Consideration.

 

A.                  License Fee.

Licensee shall pay to WARF a license fee of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] due and payable within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the Effective Date.

B.                  Royalty.

(i)                  In addition to the Section 4A license fee, Licensee (and its sublicensees) shall pay to WARF, as “earned royalties,” a royalty calculated as a percentage of the Net Sales of Products in accordance with the terms of this Agreement.  The royalty is deemed earned as [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].  The royalty rate shall remain fixed while this Agreement is in effect according to the following schedule:

 

(ii)                For Therapeutic Products the royalty is set at a rate of:

 

[*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]

 

(iii)               For Related Therapeutic Products the royalty is set at a rate of:

(iv)             For Research Products, the royalty is set at a rate of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of Net Sales.

(v)               For Diagnostic Products, the royalty is set at a rate of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of Net Sales.

(vi)              If Licensee is required to make payments to a third party (who is not an Affiliate or Development Partner) for a license or similar right to such third party’s patents, in the absence of which right or license Licensee could not legally make, use or sell Products, then the royalty payable under this Section 4B shall be reduced by [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] for each additional [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of royalties payable to such third parties on that Product; provided, however, that the adjusted royalty rate to WARF will be no less than [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the applicable royalty rate payable to WARF under this Agreement for such Products.

Page 5 of 23

(vii)            In the event that the sale, lease, or other transfer by Licensee of Products under this Agreement also requires payment to WARF of royalties under any other agreement between WARF and Licensee, the cumulative earned royalties owed to WARF for that Product under all such agreements shall not exceed the single highest royalty as set forth in those agreements.  Licensee shall pay to WARF royalties under all such agreements individually and on a pro rata basis.  (For example, if Licensee owes to WARF a [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] earned royalty under this Agreement and a [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] earned royalty under a separate agreement, the cumulative royalties owed to WARF shall be [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission], but shall be paid proportionately under each agreement in payments of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] under this Agreement and [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] on the other.)

(viii)            Given the particular Licensed Patents of this Agreement, rather than requiring Licensee to pay earned royalties under a Licensed Patent that is a pending patent application which has not issued as of the Effective Date (“Licensed Patent Application”), WARF is willing to permit Licensee to defer such amounts as follows [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].

C.                  [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]

D.                  Minimum Royalty.

Starting in calendar year 2014, Licensee shall pay to WARF a minimum royalty of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] per calendar year or part thereof during which this Agreement is in effect against which any earned royalty paid for the same calendar year will be credited.  The minimum royalty for a given year shall be due at the time payments are due for the calendar quarter ending on December 31.  It is understood that the minimum royalties will apply on a calendar year basis, and that sales of Products requiring the payment of earned royalties made during a prior or subsequent calendar year shall have no effect on the annual minimum royalty due WARF for any other given calendar year.

E.                   Patent Fees and Costs.

Licensee shall pay to WARF [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] toward reimbursement of the costs associated with preparing, filing and maintaining the Licensed Patents, which shall be due on the same date as the License Fee of Section 4A is due.

F.                   Milestones.

Licensee shall pay to WARF the amounts detailed below within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days of the first achievement of the corresponding milestones for each Product developed by Licensee (or by a sublicensee):

Page 6 of 23

(i)                 [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] upon first dosing of a human patient with a Product.

(ii)                [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] upon first dosing of a human patient with a Product in a pivotal clinical trial designed to provide statistically significant safety and efficacy data to support the filing of a biologics license application or for registration of a Product with the FDA, EMA or similar regulatory bodies in a nation listed as one of the top [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] world pharmaceutical markets by IMS Health or a similar broadly recognized authority in pharmaceutical market analysis.

(iii)              [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] upon receipt of marketing authorization for a Product from the FDA, EMA or similar regulatory bodies in a nation listed as one of the top [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] world pharmaceutical markets by IMS Health or a similar broadly recognized authority in pharmaceutical market analysis.

Notwithstanding the foregoing, in the event the indication that is the subject of the clinical trial set forth in Section 4F(ii) or the marketing authorization set forth in 4F(iii) has been designated by the applicable regulatory authority as an orphan indication, the corresponding milestone payment set forth in Section 4F(ii) or Section 4F(iii) shall be reduced by [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]; provided however that a second payment of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the applicable milestone payment shall be due upon the first achievement of the corresponding milestone for that Product in a non-orphan indication.

G.                  Accounting; Payments.

(i)                 Amounts owing to WARF under Section 4B and 4C or 2C(d) of this Agreement shall be paid on a quarterly basis, with such amounts due and received by WARF on or before the forty-fifth (45th) day following the end of the calendar quarter ending on March 31, June 30, September 30 or December 31 in which such amounts were earned.  [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].

(ii)               Except as otherwise directed, all amounts owing to WARF under this Agreement shall be paid in U.S. dollars.  All royalties owing with respect to the Net Sales and other fees are stated in currencies other than U.S. dollars shall be converted at the rate shown in the Federal Reserve Noon Valuation ‐ Value of Foreign Currencies on the day preceding the payment.  WARF is exempt from paying income taxes under U.S. law.  Therefore, all payments due under this Agreement shall be made without deduction for taxes, assessments, or other charges of any kind which may be imposed on WARF by any government outside of the United States or any political subdivision of such government with respect to any amounts payable to WARF pursuant to this Agreement.  All such taxes, assessments, or other charges shall be assumed by Licensee or its sublicensees.

Page 7 of 23

(iii)              A full accounting showing how any amounts owing to WARF under Section 4B have been calculated shall be submitted to WARF on the date of each such payment.  Such accounting shall be on a per‐country and Product line, model or tradename basis and shall be summarized on the form shown in Appendix C of this Agreement.  In the event no payment is owed to WARF, a statement setting forth that fact shall be supplied to WARF.

Section 5.                      Certain Warranties.

A.                 WARF warrants that it has the right to grant the licenses granted to Licensee in this Agreement.  Nothing in this Agreement shall, however, be construed as:  (i) a warranty or representation by WARF or Licensee as to the validity or scope of any of the Licensed Patents; (ii) a warranty or representation that anything made, used, sold or transferred under the license granted in this Agreement will or will not infringe patents of third parties; (iii) an obligation to furnish any assistance, or know-how not provided in the Licensed Patents or any materials or services other than those specified in this Agreement; or (iv) an obligation to file any patent application or secure or maintain any patent right.

B.                  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, WARF MAKES NO OTHER REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO THE MERCHANTIBILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR THE NON-INFRINGEMENT OR USE OF ANY PRODUCT, OR WITH RESPECT TO THE USE, SALE OR OTHER DISPOSITION BY LICENSEE, ITS SUBLICENSEE(S), OR THEIR VENDEES OR OTHER TRANSFEREES, OF PRODUCTS INCORPORATING OR MADE BY USE OF THE INVENTIONS LICENSED, UNDER THIS AGREEMENT.

C.                  TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL WARF OR ITS TRUSTEES, DIRECTORS, OFFICERS AND EMPLOYEES (INCLUDING WITHOUT LIMITATION ANY INVENTORS OF THE LICENSED PATENTS) BE LIABLE FOR ANY INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

D.                  Licensee represents and warrants that Products produced under the license granted herein shall be manufactured substantially in the United States as required by 35 U.S.C § 204 [for clarity, such requirement shall apply only to Products utilizing Licensed Patents or Wisconsin Materials whose development was funded at least in part by the Federal government] and applicable regulations of Chapter 37 of the Code of Federal Regulations.

Section 6.                      Recordkeeping.

A.                  Licensee and its sublicensee(s) shall keep books and records sufficient to verify the accuracy and completeness of Licensee’s and its sublicensee(s)’s accounting referred to above, including without limitation inventory, purchase and invoice records relating to any Products sold under this Agreement.  In addition, Licensee shall keep books and records sufficient to verify the accuracy and completeness of Licensee’s Development Reports.  Such documentation may include, but is not limited to, invoices for studies, laboratory notebooks, internal job cost records, and filings made to the Internal Revenue Department to obtain tax credit, if available, for research and development.  All such books and records shall be preserved for a period not less than [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] years after they are created during and after the term of this Agreement.

Page 8 of 23

B.                   Licensee and its sublicensee(s) shall take all steps reasonably necessary so that WARF may, within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days of its request, review Licensee’s books and records to allow WARF to verify the accuracy of Licensee’s Development Reports, the development and royalty reports of its sublicensee(s), and the payments made to WARF.  Such review will be performed no more than annual and by an attorney or registered CPA and scientific expert designated by WARF at WARF’s expense upon reasonable notice and during regular business hours.

C.                  If a royalty payment deficiency is determined, Licensee and its sublicensee(s), as applicable, shall pay the royalty deficiency outstanding within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days of receiving written notice thereof, plus interest on outstanding amounts as described in Section 4G(i).  If a royalty payment deficiency for a calendar year exceeds the lesser of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the royalties paid for that year or [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission], then Licensee or its sublicensee(s) shall be responsible for paying WARF’s out‐of‐pocket expenses incurred with respect to such review.

Section 7.                      Term and Termination.

A.                  The term of this Agreement shall begin on the Effective Date and continue until (i) with respect to the Licensed Patents, the expiration of the last to expire Licensed Patent, unless otherwise earlier terminated as provided herein and (ii) with respect to the Wisconsin Materials (per the attached Wisconsin Materials Addendum), until this Agreement is terminated by either Party as provided herein.

B.                  Licensee may terminate this Agreement at any time by giving at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days written and unambiguous notice of such termination to WARF. WARF may terminate this Agreement if the payment of earned royalties under Section 4B, once begun, ceases for more than [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].

C.                 WARF may terminate this Agreement prior to the Date of First Commercial Sale by giving Licensee at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]days written notice if Licensee and/or its Collaborators, Contract Service Providers and Development Partners fail to spend at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] per year to develop Products in [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] successive calendar years.

D.                  If Licensee at any time (i) defaults in the timely payment of any monies due to WARF; or the timely submission to WARF of any report, or (ii) commits any breach of any other covenant herein contained, and Licensee fails to remedy any such breach or default within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days after written notice thereof by WARF, or if Licensee commits any act of bankruptcy, becomes insolvent, is unable to pay its debts as they become due, files a petition under any bankruptcy or insolvency act, or has any such petition filed against it which is not dismissed within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]days, or if Licensee or a sublicensee offers any component of the Licensed Patents, Wisconsin Materials or Licensed Materials to its creditors, WARF may, at its option, terminate this Agreement by giving notice of termination to Licensee.

Page 9 of 23

E.                   Upon termination of this Agreement, the licenses granted herein shall immediately terminate.  In the event of termination under Section 7B or 7C, Licensee shall have [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days to cease all activities involving the use of Licensed Materials, Wisconsin Materials and Derivative Materials for any purpose, and shall destroy all Licensed Materials, Wisconsin Materials and Derivative Materials in its possession.  Licensee and its sublicensee(s) shall remain obligated to pay any outstanding amounts owed as of the date of termination and all such amounts shall be paid within forty-five (45) days of termination.

F.                   For clarity, the obligations of Sections 5B, 5C, 11, 13, 14, 16, and 18 shall survive any termination of this Agreement.

Section 8.                      Assignability; Change of Control; Affiliates.

Licensee shall not assign or transfer this Agreement, nor any of the rights granted herein, without the prior written consent of WARF (which shall not be unreasonably withheld), except pursuant to a sale of all or substantially all of the assets relating to Products.  Licensee shall notify WARF in writing at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days in advance of any such assignment and, with respect to a transfer of this Agreement to any non-Affiliate, pay to WARF a fee of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] to allow the transfer of the license granted herein to that non-Affiliate to whom control has been transferred, within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] days after the occurrence of such event.  For clarity, in no event shall a bona fide financing transaction, or series of bona fide financing transactions, of Licensee including one or more financial investors be deemed to be a sale of the assets of Licensee and no transfer fee under this Section 8 shall be due to WARF in such event.

In the event that an Affiliate who has previously agreed to sign on and be bound by the terms and obligations of this Agreement should subsequently cease to be an Affiliate of Asterias Biotherapeutics through dilution of Asterias’ ownership to <50% through a series of bona fide financing transactions, such Affiliate’s rights under this Agreement shall survive such Affiliate cessation date for a period of [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission], during which WARF and such Affiliate shall negotiate a direct license agreement with terms substantially identical to those herein, except for: (i) division of the Annual Minimum Royalty due under Section 4D, which division shall be worked out between Asterias and such Affiliate and this Agreement will be amended to reflect such division, and (ii) any other changes as mutually agreed upon between such Affiliate and WARF.  For clarity, no transfer fee under this Section 8, sublicense fee under Section 4C (except for any amounts that may remain outstanding under this Agreement), upfront license fee, or additional patent fee shall be due to WARF for the establishment of such a direct license agreement with such Affiliate assuming such foregoing amounts have been satisfied under this Agreement and no additional intellectual property or proprietary rights have been added to such to-be-negotiated license agreement.

Page 10 of 23

Section 9.                      Contest of Validity.

  

A.                Licensee and its sublicensee(s) must provide WARF at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] months prior written notice before filing any action that contests the validity of any Licensed Patent during the term of this Agreement.

B.                  If Licensee or its sublicensee(s) files any action contesting the validity of any Licensed Patent, the filing party shall pay [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].  Moreover, should the outcome of such contest determine that any claim of a Licensed Patent challenged by the filing party is valid and would be infringed by a Product sold by the filing party if not for the license granted by this Agreement, such filing party shall thereafter, and for the remaining term of this Agreement [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].

C.                  If Licensee or its sublicensee(s) contests the validity of any Licensed Patent during the term of this Agreement, Licensee shall pay (and shall require its sublicensee(s) to agree to pay) to WARF all royalties due under the Agreement during the period of challenge.  For the sake of clarity, Licensee or the sublicensee shall not pay such amounts into any escrow or other account, but directly to WARF.

Section 10.                   Enforcement.

WARF intends to protect the Licensed Patents against infringers, or otherwise act to eliminate infringement when, in WARF's sole judgment and discretion, such action may be reasonably necessary, proper and justified.  In the event that Licensee or its sublicensee believes there is infringement of any Licensed Patents, Licensee shall provide WARF with notification and reasonable evidence of such infringement.  If WARF takes action to remedy the infringement, Licensee or such sublicensee agrees to provide reasonable assistance to WARF as requested by WARF and at WARF’s expense.

Section 11.                   Indemnification and Insurance.

A.                  Licensee and its sublicensee(s) shall, at all times during the term of this Agreement and thereafter, indemnify, defend and hold WARF, WiCell, the Morgridge Institute for Research and the University of Wisconsin (the “University”), and their respective trustees, directors, officers, shareholders and employees (including without limitation any inventors of the Licensed Patents) (each, an “Indemnitee”) harmless against all liabilities, demands, damages, settlements, suits, claims, proceedings, costs and expenses, including legal expenses and reasonable attorneys fees, arising out of or relating to the death of or injury to any person or persons or any damage to property, due to the sale, marketing, use, or manufacture of Products, Licensed Materials, Wisconsin Materials, or any Derivative Materials or Developments by Licensee and all sublicensees hereunder.  WARF at all times reserves the right to select and retain counsel of its own to defend WARF’s interests in any such proceeding.

B.                  Licensee warrants that it now maintains and will continue to maintain liability insurance coverage reasonably appropriate to the risk involved in use, sale, marketing, and manufacture of Products, the Licensed Materials, Wisconsin Materials, and any Derivative Materials, or the performance of Services, under this Agreement, and that such insurance coverage is sufficient to cover WARF and the inventors of the Licensed Patents, the Wisconsin Materials and Licensed Materials as additional insureds.  Upon WARF’s request, Licensee will present evidence to WARF that such coverage is being maintained.

Page 11 of 23

Section 12.                   Use of Names.

Neither party shall use the other’s name, and Licensee and its sublicensee(s) shall not use the name of any inventor of the Licensed Patents, or the name of WARF, WiCell Research Institute, or the University, in any form of publicity without the prior written approval of the entity or person whose name is being used, except where a disclosure is required by any applicable law or the rules of any securities exchange.  Notwithstanding the foregoing, WARF shall have the right to disclose to existing and potential licensees the fact that WARF has entered into this Agreement with Licensee.

Section 13.                   Confidentiality.

A.                 Both parties agree to keep any information identified as confidential by the disclosing party, confidential using methods at least as stringent as each party uses to protect its own confidential information.  Confidential information shall include, without limitation, this Agreement and its terms, as well as any information provided to WARF under Section 3.  Except as may be authorized in advance in writing by WARF, Licensee shall only grant access to WARF’s Confidential Information to its sublicensee(s) and those employees of Licensee and its sublicensee(s) involved in research relating to the Licensed Patents.  Licensee shall require its sublicensee(s) and all such employees to be bound by terms of confidentiality no less restrictive than those set forth in this Section 13.  The confidentiality and use obligations set forth above apply to all or any part of information disclosed hereunder except to the extent that:

(i)                 the receiving party can show by written record that they possessed the information prior to its receipt from the disclosing party;

(ii)                 the information was already available to the public or became so through no fault of the receiving party;

(iii)               the information is subsequently disclosed to the receiving party by a third party that has the right to disclose it free of any obligations of confidentiality; or

(iv)               five (5) years have elapsed from the expiration or termination of this Agreement.

B.                 Nothing contained in this Section 13 shall be construed to limit or preclude WARF from negotiating or entering into any agreements with third parties under terms and conditions similar to that set forth in this Agreement.

Section 14.                   United States Government Interests.

It is understood that if the United States Government (through any of its agencies or otherwise) has funded research, during the course of or under which any of the inventions of the Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C. § 200‐212 and applicable regulations of Chapter 37 of the Code of Federal Regulations, to a nonexclusive, nontransferable, irrevocable, paid‐up license to practice or have practiced the inventions of the Licensed Patents for governmental purposes.  Any license granted to Licensee or any of its sublicensees under this Agreement shall be subject to such right.

Page 12 of 23

Section 15.                   Patent Marking.

Licensee and its sublicensee(s) shall mark all service agreements, Products or product packaging with the appropriate patent number reference in compliance with the requirements of the laws of the United States of America, including specifically, 35 U.S.C. § 287.

Section 16.                   Miscellaneous.

A.                 This Agreement shall be governed by and construed in all respects in accordance with the laws of the State of Wisconsin, without reference to its conflicts of laws principles.

B.  The parties hereto are independent contractors and not joint venturers or partners.

C.  If Asterias or any of its Affiliates also has rights under the BioTime Research License, the terms and obligations of this Agreement shall control.

D.                 If the enforcement of any provisions of this Agreement are or shall come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the parties or this Agreement, those provisions shall be deemed automatically deleted, if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement shall remain in full force and effect.  If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect, the parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under the applicable laws and regulations.

E.                 WARF and Licensee have each been represented by counsel who participated in the preparation of this Agreement.  This Agreement reflects a negotiated compromise between the parties.  Neither party shall be considered to be the drafter of this Agreement or any of its provisions for the purpose of any statute, case law or rule of interpretation or construction that would or might cause any provision to be construed against the drafter of this Agreement.  The Section headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

F.                  This Agreement is not intended to be for the benefit of and shall not be enforceable by any third party.  Nothing in this Agreement, express or implied, is intended to or shall confer on any third party any rights (including third-party beneficiary rights), remedies, obligations or liabilities under or by reason of this Agreement.  This Agreement shall not provide third parties with any remedy, claim, reimbursement, cause of action or other right in excess of those existing without reference to the terms of this Agreement.  No third party shall have any right, independent of any right that exists irrespective of this Agreement, to bring any suit at law or equity for any matter governed by or subject to the provisions of this Agreement.

G.                  Licensee acknowledges and agrees that damages may not be an adequate remedy in the event of a breach of this Agreement by Licensee.  Licensee therefore agrees that WARF shall be entitled to seek immediate and permanent injunctive relief from a court of competent jurisdiction in addition to any other rights or remedies otherwise available to WARF.

H.                 Waiver by either party of a single breach or default, or a succession of breaches or defaults, shall not deprive such party of any right to terminate this Agreement in the event of any subsequent breach or default.

Page 13 of 23

Section 17.                   Notices.

Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and shall be deemed to have been given at the earlier of the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, or delivery by a professional courier service or the time when sent by certified or registered mail addressed to the party for whom intended at the address below or at such changed address as the party shall have specified by written notice, provided that any notice of change of address shall be effective only upon actual receipt.

	 	
(a)

	
Wisconsin Alumni Research Foundation

Attn:  Contracts Manager

614 Walnut Street

Madison, Wisconsin  53726

	 	
(b)

	
Asterias Biotherapeutics, Inc.

Attn:  Katharine Spink

230 Constitution Dr.

Menlo Park, CA 94025                        

 

Section 18.                   Integration.

This Agreement together with the Wisconsin Materials Addendum, attached hereto, constitutes the full understanding between the parties with reference to the subject matter hereof, and no statements or agreements by or between the parties, whether orally or in writing, except as provided for elsewhere in this Section 18, made prior to or at the signing hereof, shall vary or modify the written terms of this Agreement.  Neither party shall claim any amendment, modification, or release from any provisions of this Agreement by mutual agreement, acknowledgment, or otherwise, unless such mutual agreement is in writing, signed by both parties, and specifically states that it is an amendment to this Agreement.

Section 19.                   Authority.

The persons signing on behalf of WARF and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the party for whom they have signed.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement on the dates indicated below.

	
WISCONSIN ALUMNI RESEARCH FOUNDATION (“WARF”)

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
s/Leigh Cagan

	
 

	
Date:  10/7, 2013

	
	
 

	
Leigh Cagan, Chief Technology Commercialization Officer

	
 

	
 

	
 

					
	
ASTERIAS BIOTHERAPEUTICS, INC. (“LICENSEE”)

			
	 			
	
By:

	
s/Katharine Spink

		
Date:  October 1, 2013

	
	
 

	
Katharine Spink, Vice President and Chief Operating Officer

	
 

	
 

	
 

Page 14 of 23

APPENDIX A

A.                  “Affiliate” and “Affiliates” mean any entity controlled by Asterias.  As used herein, “control” shall refer to and mean ownership of greater than fifty percent (>50%) or more of the outstanding voting equity of an entity.

 

B.                   “Collaborator” means an academic, non-profit research institution with which Licensee enters into a written agreement pursuant to and solely to the extent permitted by Section 2C for a collaborative project or projects for the further research on and/or development of the Licensed Materials, Wisconsin Materials, Derivative Materials and/or Products in support of Licensee's development or commercialization of one or more Products.

 

C.                  “Contract Service Provider” means a third party with which Licensee enters into a written agreement pursuant to and solely to the extent permitted by Section 2C for the provision of specific services in support of Licensee’s development or of one or more Products on behalf of Licensee or its Collaborator.

 

D.                “Date of First Commercial Sale” means the date when cumulative sales to the retail market of Therapeutic Products exceed [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission].

 

E.                   “Derivative Materials” means any compositions or materials derived by Licensee or its sublicensee(s) from the use of the Wisconsin Materials, or produced by the use of the Wisconsin Materials by Licensee or its sublicensee(s), or which incorporate wholly or partially the Wisconsin Materials, including without limitation, fully or partially differentiated cells or cell lines derived from the Wisconsin Materials by Licensee or its sublicensee(s).

 

F.                   “Development” and “Developments” means (i) Derivative Materials; (ii) any inventions, discoveries or developments, whether patentable, that are conceived of, reduced to practice, discovered, tested or developed through the use of the inventions of the Licensed Patents, Wisconsin Materials or Derivative Materials by Licensee or its sublicensee(s); and (iii) any compositions, products or other materials of Licensee or its sublicensee(s) in which the Wisconsin Materials or Derivative Materials were used in any way in their discovery or testing.

 

G.                   “Development Partner” means a third party with which Licensee enters into a written agreement pursuant to and solely to the extent permitted by Section 2C for the further development and/or commercialization of Products initially substantially developed by Licensee.

 

H.                “Development Report” means the written report provided under Section 3 describing each Development and Product to be patented or commercialized by Licensee or a sublicensee.

 

I.                  “Diagnostic Products” means products or services that (i) are used in the diagnosis, prognosis, screening or detection of disease in humans, and (ii) (a) employ, or are in any way produced or manufactured by the practice or use of the inventions of the Licensed PatentsDerivative Materials or Wisconsin Materials, and/or (b) would otherwise constitute infringement of any claims of the Licensed Patents.

 

J.                    “Internal Research” means research conducted internally by Licensee at Licensee’s facilities.

 

K.                   “Licensed Field” is limited to the field of Products.

Page 15 of 23

L.                  “Licensed Materials” means primate (including human) embryonic stem cells covered by the Licensed Patents and which meet the following conditions:

 

(i)                    For embryonic stem cells created prior to April 26, 2005, the embryonic stem cell must be either: (1) listed on the NIH Human Embryonic Stem Cell Registry at http://escr.nih.gov; or (2) derived from excess embryos created for the purpose of in vitro fertilization with appropriate consent of the donor couple and not for the purpose of creating embryonic stem cells; or (3) derived from embryos created specifically for research purposes either by in vitro fertilization or by somatic cell nuclear transfer, for which the following additional conditions apply:  (a) the embryo may not have been maintained in vitro for more than 14 days; (b) the gamete donor(s) and somatic cell donor (if any) made the donation without payment beyond reimbursement for reasonable expenses associated with donation; (c) in the case of egg donation, the donor was fully informed of the risks to herself; (d) the gamete donor(s) and somatic cell donor (if any) were fully informed of the purposes to which their donated materials would be put; (e) the research could not be done equally well using surplus IVF embryos originally created for reproductive purposes; (f) the research protocol, including gamete collection, somatic cell collection, embryo management and stem cell derivation is approved by an appropriate Institutional Review Board; and (g) protections are in place to prevent misappropriation of embryos created specifically for research.

(ii)                  For embryonic stem cells created from embryos created after April 26, 2005, the embryonic stem cells must be derived from embryos and under conditions in compliance with the “Guidelines for Human Embryonic Stem Cell Research” established by the National Research Council Institute of Medicine of the National Academies (the “NAS Guidelines”).

(iii)                For embryonic stem cells created after April 26, 2005 from embryos generated prior to April 26, 2005, and which do not meet the NAS Guidelines, the embryonic stem cells must meet one of the conditions set forth in paragraph (i) above and be created using protocols substantially in compliance with the requirements of the NAS Guidelines.

M.               “Licensed Patents” means those patents and patent applications listed on Appendix B attached hereto and all foreign equivalents owned by or licensed to WARF.

 

N.                  “Licensed Territory” means worldwide.

 

O.                  “Net Sales” [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]

 

In the event that a Product is sold in combination with another product, component or service for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales for purposes of calculating the amounts due under Section 4B shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B), where “A” is the average selling price during the previous calendar quarter of the Product sold separately and “B” is the average selling price during the previous calendar quarter of the product(s), component(s) and/or service(s) combined therewith.  Where a Product is sold only as a component of a larger product or system and not as a stand-alone product, then the Net Sales amount shall be deemed to be the amount received by Licensee or sublicensees for the entire product containing the Product multiplied by a number, the numerator of which is Licensee’s (or the sublicensee’s) costs for the Product and the denominator of which is Licensee’s (or the sublicensee’s) costs for the entire product sold by Licensee (or the sublicensee) that includes the Product.

 

P.                  “Non-Commercial Research Purposes” means the use for internal academic research purposes or other internal not-for-profit or scholarly purposes not involving the use of the technology: (1) to perform services for a fee; or (2) for the production or manufacture of products for sale to third parties.

Page 16 of 23

Q.                  “Products” means any Research Products, Diagnostic Products, Therapeutic Products, and Related Therapeutic Products.

 

R.                  “Related Therapeutic Product” means products or services that (i) are used in the treatment of disease in humans, and (ii) are in any way produced or manufactured using, and/or incorporate any Wisconsin Material or

 

Derivative Material, but do not employ the practice or otherwise constitute infringement of any [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the Licensed Patents.

S.                   “Research products” means products or services that (i) are used as research tools, including in drug discovery and development, and (ii) (a) employ, or are in any way produced or manufactured by, the practice or use of the inventions of the Licensed Patents, Derivative Materials or the Wisconsin Materials, and/or (b) would otherwise constitute infringement of any claims of the Licensed Patents.

 

T.                   “Therapeutic Products” means products or services that (i) are used in the treatment of disease in humans, and (ii) (a) employ, or are in any way produced or manufactured by, the practice or use of a [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the Licensed Patents, and/or (b) would but for this Agreement otherwise constitute infringement of any [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] of the Licensed Patents.

 

U.                 [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission]

V.                   “Wisconsin Materials” is defined in the attached Wisconsin Materials Addendum.

Page 17 of 23

LICENSED PATENTS

APPENDIX B

 

	

REFERENCE

NUMBER

	
COUNTRY

	

APPLICATION

SERIAL NUMBER

	
FILING DATE

	
 PATENT

 

METHOD OF IN VITRO DIFFERENTIATION OF TRANSPLANTABLE NEURAL PRECURSOR CELLS FROM PRIMATE EMBRYONIC STEM CELLS

(Ian Duncan, James Thomson, Su-Chun Zhang)

	
P01258US

	
UNITED STATES

	
09/970382

	
10/03/2001

	
6887706

	
P04277US

	
UNITED STATES

	
10/928805

	
08/27/2004

	
7588937

	
P07050US

	
UNITED STATES

	
11/594455

	
11/08/2006

	
7972850

	
P07445US

	
UNITED STATES

	
11/932582

	
10/31/2007

	
8153424

	
P09335IL

	
ISRAEL

	
198450

	
08/27/2004

	
198450

 

PRIMATE EMBRYONIC STEM CELLS

(James Thomson)

	
P02115US

	
UNITED STATES

	
09/982637

	
10/18/2001

	
7029913

	
P05206US

	
UNITED STATES

	
11/036245

	
01/14/2005

	
7582479

	
P08333US

	
UNITED STATES

	
12/047135

	
03/12/2008

	
7781216

	
P96014US

	
UNITED STATES

	
08/591246

	
01/18/1996

	
5843780

	
P98222US

	
UNITED STATES

	
09/106390

	
06/26/1998

	
6200806

 

SERUM FREE CULTIVATION OF PRIMATE EMBRYONIC STEM CELLS

(James Thomson)

	
P99275US

	
UNITED STATES

	
09/522030

	
03/09/2000

	
7005252

	
P03122US

	
UNITED STATES

	
10/430497

	
05/06/2003

	
7217569

	
W05007US

	
UNITED STATES

	
11/078737

	
03/11/2005

	
7439064

	
W09003US

	
UNITED STATES

	
12/489978

	
06/23/2009

	
 

	
P07322AU

	
AUSTRALIA

	
2007200575

	
03/02/2001

	
2007200575

 

METHOD OF MAKING EMBRYOID BODIES FROM PRIMATE EMBRYONIC STEM CELLS

(James Thomson, Jennifer Swiergiel, Vivienne Marshall)

	
P99276US

	
UNITED STATES

	
09/510444

	
02/21/2000

	
6602711

	
P03410US

	
UNITED STATES

	
10/632399

	
05/06/2003

	
7220584

Page 18 of 23

APPENDIX C

WARF ROYALTY REPORT

 

	
Licensee:

	

		
Agreement No:  

	

	
 

	
 

		
 

	
 

	
Inventor:

	

		
WARF Ref. #:

	
P

	 				
	Period Covered:  	From:               /                    /		Through:	/                    /
	 				
	Prepared By:	  		Date:	  
	 				
	
Approved By:

	

		
Date:

	

	
 

	
 

		
 

	
 

If license covers several major Product lines, please prepare a separate report for each line, and combine all Product lines into a summary report.

 

	
Report Type:

	
q  Single Product Line Report:    

	
 

		
	
 

	
 

	
 

	
 

	
 

		
	
 

	
q  Multiproduct Summary Report:Page 1 of ______ Pages

	
 

	
 

	
 

	
 

	
 

		
	 	q  Product Line Detail.  Line:	  	Tradename:  	  	Page:  	  

 

	
Report Currency:

	
q  U. S. Dollars      q  Other  

	

	

	

	
 

	
Gross

	
* Less:

	
Net

	
Royalty

	
Period Royalty Amount

	
Country

	
Sales

	
Allowances

	
Sales

	
Rate

	
This Year

	
Last Year

	
U.S.A.

	
 

	
 

	
 

	
 

	
 

	
 

	
Canada

	
 

	
 

	
 

	
 

	
 

	
 

	
Europe:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
Japan

	
 

	
 

	
 

	
 

	
 

	
 

	
Other:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
TOTAL:

	
 

	
 

	
 

	
 

	
 

	
 

Total Royalty: _______________  Conversion Rate: ____________  Royalty in U.S. Dollars: $                                                 

The following royalty forecast is non-binding and for WARF’s internal planning purposes only:

Royalty Forecast Under This Agreement:  Next Quarter:__________  Q2:__________  Q3:__________  Q4:__________

 

	

* On a separate page, please indicate the reasons for returns or other adjustments if significant.

Also note any unusual occurrences that affected royalty amounts during this period.

To assist WARF’s forecasting, please comment on any significant expected trends in sales volume.

Page 19 of 23

APPENDIX D

DEVELOPMENT REPORT

	A.	Date development plan initiated and time period covered by this report.

B.                  Development Report (4-8 paragraphs).

		1.	Activities completed since last report including the object and parameters of the development, when initiated, when completed and the results.

		2.	Activities currently under investigation, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected date of completion.

	C.	Future Development Activities (4-8 paragraphs).

		1.	Activities to be undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected starting and completion dates.

		2.	Estimated total development time remaining before a Product will be commercialized.

	D.	Changes to initial development plan (2-4 paragraphs).

		1.	Reasons for change.

		2.	Variables that may cause additional changes.

	E.	Items to be provided if applicable:

		1.	Information relating to Product that has become publicly available, e.g., published articles, competing products, patents, etc.

		2.	Development work being performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future uses of third parties including reasons why and type of work.

		3.	Update of competitive information trends in industry, government compliance (if applicable) and market plan.

PLEASE SEND DEVELOPMENT REPORTS TO:

Wisconsin Alumni Research Foundation

Attn.:  Contract Manager

614 Walnut Street

Madison, WI 53726

Page 20 of 23

APPENDIX E

DEVELOPMENT PLAN

(To be provided by Licensee within [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] months of Effective Date)

Page 21 of 23

WISCONSIN MATERIALS ADDENDUM

This Addendum is made effective the 1st day of October, 2013, by and between Wisconsin Alumni Research Foundation (“WARF”), a nonprofit Wisconsin corporation, and Asterias Biotherapeutics Incorporated (“Licensee”), a corporation organized and existing under the laws of Delaware.

WHEREAS, WARF and Licensee have entered into License Agreement No. 13-00300, effective October 1, 2013 (the “Patent Rights Agreement”), granting Licensee the right under certain Licensed Patents to make, use and receive Licensed Materials for use in Internal Research;

WHEREAS, WARF also holds certain rights in human embryonic stem cell lines developed by James A. Thomson of the University of Wisconsin – Madison, working either alone or with other researchers at the University (the “Wisconsin Materials” as defined below); and

WHEREAS, Licensee has entered into an Asset Contribution Agreement dated January 4, 2013 with Geron Corporation (“Geron”), pursuant to which certain Wisconsin Materials will be transferred to Licensee (the “ACA”); and

WHEREAS, Licensee desires to obtain from WARF rights to utilize the Wisconsin Materials in accordance with the License Agreement executed between the parties dated October 1, 2013 and the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the above premises and the mutual covenants contained herein, the parties further agree as follows:

1.            Except as otherwise provided in this Addendum, all terms and conditions previously set forth in the License Agreement shall remain in effect as set forth therein.  In the event that this Addendum and the License Agreement are inconsistent with respect to any terms and conditions pertaining to the Wisconsin Materials, the terms and provisions of this Addendum shall supersede the terms and provisions of the License Agreement.

2.             “Wisconsin Materials” shall mean the H1, H7, H9, H13 and H14 embryonic stem cell lines provided to Licensee by WARF, Geron or a third party authorized by WARF, including any progeny, unmodified derivatives, genetically modified embryonic stem cells or clones of those cells or cell lines.  Upon request of Licensee, WARF or WiCell shall provide Licensee within thirty (30) days of such request, without additional charge, two aliquots each of the following embryonic stem cell lines:  H1, H9, H7, H13 and H14.

 

3.             As used in the License Agreement, “Licensed Materials” shall further include the Wisconsin Materials; provided, however, that Licensee shall not have the right to:

	
(a)

	
intermix the Wisconsin Materials with an intact embryo, either human or nonhuman;

	(b)	implant the Wisconsin Materials or any products of the Wisconsin Materials in a uterus, including Derivative Materials derived from the Wisconsin Materials;

	
(c)

	
attempting to make whole embryos by any method using the Wisconsin Materials.

Page 22 of 23

	(d)	use the Wisconsin Materials for therapeutic purposes.

4.            Licensee agrees that on or before June 30th of each year in which this Addendum is in effect, License will submit to WARF a signed Annual Certification Statement as set forth on Exhibit A confirming compliance with the above restrictions.  Licensee agrees that it will comply with all applicable laws, regulations and government orders with respect to any use of the Wisconsin Materials, and shall, as appropriate, seek and comply with the decisions and recommendations of any applicable Institutional Review Board or similar body.

5.            Wisconsin Materials are the property of WARF and are being made available to Licensee as a service by WARF.  Ownership of all Wisconsin Materials, including any progeny or modified versions thereof, shall remain with WARF, regardless of whether such Wisconsin Materials are received from WARF or an authorized third party.  Any Wisconsin Materials provided hereunder will be returned to WARF or destroyed upon a material breach of any terms of this Addendum or the Patent Rights Agreement.

6.            Licensee agrees to communicate to WARF all publications and/or research results made public by Licensee based on research using the Wisconsin Materials.  In addition, any reports, publications, or other disclosure of results obtained with the Wisconsin Materials will acknowledge WARF as the original source of the Wisconsin Materials and, in the event that the Wisconsin Materials were received from an authorized third party, the conditions in which such Wisconsin Materials were maintained prior to their transfer.

7.            Licensee may not assign or transfer this Addendum, nor any of the rights granted herein, without the prior written consent of WARF, such consent not to be unreasonably withheld.  This Addendum shall be governed by and construed in all respects in accordance with the laws of the State of Wisconsin.

The persons signing on behalf of WARF and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the party for whom they have signed.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement on the dates indicated below.

	
WISCONSIN ALUMNI RESEARCH FOUNDATION

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
s/Leigh Cagan

	
 

	
Date:10/7, 2013

	
 

	
Leigh Cagan, Chief Technology Commercialization Officer

	
 

	
 

	
 

	
 

	
 

	
 

	
ASTERIAS BIOTHERAPEUTICS, INC.

		
	 		
	
By:

	
s/Katharine Spink

		
 Date: October 1, 2013

		
Katharine Spink Vice President and Chief Operating Officer

		

 

 

Page 23 of 23Exhibit 10.1

 

ROYALTY AGREEMENT

This Royalty Agreement ("Agreement") is made as of October 1, 2013 (“Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation (“Asterias”), and Geron Corp., a Delaware corporation (“Geron”).

RECITALS

WHEREAS, Asterias, BioTime, Inc. and Geron have entered into that certain Asset Contribution Agreement, dated January 4, 2013 (the “Asset Contribution Agreement”), pursuant to which Geron has transferred and assigned certain patents and patent applications to Asterias in exchange for shares of Asterias common stock; and

WHEREAS, Asterias has agreed to enter into this Agreement and pay to Geron royalties on product sales and a share of royalties received from third party licensees on the sale products covered by the Geron patents, on the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the Parties hereto agree as follows:

ARTICLE 1 ‐ DEFINITIONS

Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Asset Contribution Agreement.   The following defined terms shall have the meanings ascribed to them in this Article 1:

1.1            “Affiliate” means, with respect to Geron or Asterias, any corporation, limited liability company, limited partnership or other entity in control of, controlled by, or under common control with such party.

1.2            “Combination Product” means any Product which includes one or more active ingredients other than a Product in combination with a Product, including a fixed-dose combination product.

1.3            “Confidential Information” means any and all information that is contained in any report under Section 3.1, or disclosed by Asterias or any of its Affiliates to Geron or its Representatives in connection with any audit under Section 3.2.

1.4            "Contributed Patents" means all of the patents, patent applications and patent rights to inventions identified on Schedule 1 and all active prosecution cases related thereto.

1.5            “Excluded Product” means any Product covered by one or more patents licensed to or from Geron under the cross-license among Geron, ES Cell International Pte Ltd. and Cell Cure Neurosciences, Ltd.

 

1.6            “First Commercial Sale” means the first sale for end-use or consumption of a Product.

1.7            "Net Sales" means the total gross amount invoiced and paid to Asterias or any Affiliate of Asterias for sales or transfers of Products to an unrelated third party anywhere in the world,

 

(a) less deductions for:

 

(i)            freight, postage and duties and transportation charges directly related to the Products sold (including handling and insurance with respect thereto);

 

(ii)            sales, value added and excise taxes or customs paid, and any other similar governmental charges imposed upon the sale of the Products that are not recoverable;

 

(iii)            allowances, chargebacks or credits actually granted by Asterias or its Affiliates to end-users not in excess of the selling price of Products, on account of rejection, outdating, recalls or return of Products; and

 

(iv)            rebates, reimbursements, fees or similar payments:  (1) to wholesalers and other distributors, pharmacies and other retailers, buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, hospitals, clinics, government agencies or authorities or other institutions or health care organizations; or (2) to patients and other third parties arising in connection with any program applicable to Products under which the Asterias or its Affiliates provide to low income, uninsured or other patients the opportunity to obtain one or more Products at a reduced cost.

For the avoidance of doubt, if a single item falls into more than one of the categories set forth in clauses “(a)(i)” through “(a)(iv)” above, such item may not be deducted more than once.  For purposes of determining Net Sales, a Product shall be deemed to be sold when invoiced.

 

(b) Net Sales for any Combination Product in a country shall be calculated as follows:

 

(i)            Where all active ingredients in such Combination Product are sold separately in the country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country as determined above by the fraction A/(A+B), where A is the net invoice price of the Product as sold separately in such country, and B is the sum of the net invoice prices of the other active ingredients in the combination.

  

(ii)            If the Product component of the Combination Product is sold separately in the country, but none of such other active ingredient(s) is sold separately in such country, Net Sales for the purpose of determining royalties due hereunder for the Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/C, where A is the net invoice price of such Product component as sold separately, and C is the net invoice price of the Combination Product.

2

(iii)            If the Product component of the Combination Product is not sold separately in the country, but the other active ingredient(s) are sold separately in such country, Net Sales for the purpose of determining royalties due hereunder for the Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-D)/C, where: C is the net invoice price, in such country, for the Combination Product, and D is the sum of the net invoice prices charged for the other active ingredients in the Combination Product.

 

(iv)            If none of the Product component and the other active ingredients are sold separately in the country, Net Sales for the purposes of determining royalties due hereunder for the Combination Product will be determined by mutual agreement of the parties, according to the formula D/(D+E), where D is the fair market value of the portion of the Combination Products that contains the Product, and E is the fair market value of the portion of the Combination Product containing the other active ingredients in such Combination Product.  In applying the foregoing formulas, Asterias (or its Affiliate if the sale was by an Affiliate) shall act in good faith and accordance with Asterias’ (or its Affiliate if the sale was by an Affiliate) regular accounting methods, consistently applied.

 

(c) If a Product is sold for consideration other than cash, the Net Sales from such sale shall be deemed the then fair market value of such Product.

1.8            “Partially Excluded Product” means any Product which includes one or more Products that are not Excluded Products in combination with one or more Excluded Products.

1.9            "Product" means any composition or product the manufacture, use, sale, offer for sale, or importation of which would constitute, but for ownership or licensed rights to use one or more of the Contributed Patents, an infringement of any Valid Claim under one or more Contributed Patents.  The term “Product”, as used herein, shall include Combination Products.

1.10            “Representatives” means, with respect to Geron or Asterias, such party’s Affiliates and its and their respective officers, directors, employees, agents, attorneys, accountants and advisors.

1.11            “Sales Agent” means any distributor, independent sales representative, consignee or other agent retained in writing by Asterias or any Affiliate of Asterias for the purpose of selling Products on behalf of Asterias and Asterias’ Affiliates.  For the avoidance of doubt, the foregoing shall not include collaborators, partners or sublicensees of Asterias or Asterias’ Affiliates who sell Products other than on behalf of Asterias or Asterias’ Affiliates.

1.12            "Term" means the period of time beginning on the Effective Date and ending on the expiration or termination date of the last Valid Claim such that no Valid Claims remain in effect in any country.

3

1.13            “Valid Claim” shall mean a claim of an issued and unexpired patent included within the Contributed Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.

For purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires:  (a) the use herein of the plural shall include the single and vice versa and the use of the masculine shall include the feminine; (b) unless otherwise set forth herein, the use of the terms “including,” “includes,” or “include” means “including but not limited to,” “includes but is not limited to,” or “include but not be limited to,” respectively; and (c) the words “herein,” “hereof,” “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular provision.  Additional terms may be defined throughout this Agreement.

ARTICLE 2- ROYALTIES

2.1                             Royalties.

 

(a)            Commencing on the First Commercial Sale of each Product by Asterias, an Affiliate of Asterias, or a Sales Agent, Asterias shall pay Geron a royalty in the amount of four percent (4%) of Net Sales of such Product.

 

(b)            In the case of sales of Products by any individual or entity other than a Sales Agent, Asterias or any Affiliate of Asterias (any such individual or entity, a “non-Affiliate”) where Asterias or any Affiliate of Asterias receives a royalty or other cash payment in respect of such Product sales, Asterias shall pay Geron fifty percent (50%) of all such royalties and other cash payments received by Asterias or such Affiliate of Asterias in respect to such Product sales; provided, however, that royalties or other such payments derived from the sales of Combination Products shall be calculated on the basis set forth for Net Sales for Combination Products specified in clauses “(b)(i)” to “(b)(iv)” of Section 1.7.   The parties acknowledge and agree that in no event will Asterias pay Geron an amount in excess of any royalty or other cash payment received by Asterias or such Affiliate of Asterias, less all cash payments owed by Asterias or such Affiliate of Asterias to third parties, in each case, with respect to such Product sales.

 

(c)            Geron will not be entitled to receive any royalties or other cash payments pursuant to this Agreement with respect to Excluded Products that are not  Partially Excluded Products.  With respect to Partially Excluded Products, any royalty on Net Sales pursuant to Section 2.1(a) or royalty or other cash payment derived  from the sales of any Partially Excluded Products pursuant to Section 2.1(b) shall be calculated on the basis set forth for Net Sales for Combination Products specified in clauses “(b)(i)” to “(b)(iv)” of Section 1.7 as if the Excluded Product(s) (together with any other active ingredient(s) that are not Products in the event that such Partially Excluded Product also constitutes a Combination Product) were the active ingredients that are not Products.

4

(d)            Asterias’ obligation to pay royalties or other cash payments on Net Sales, or with respect to royalties or other cash payments received from any non-Affiliate with respect to any Product, shall expire on a country by country basis upon the expiration of the last to expire Valid Claim covering such Product in any country where the Product is sold.

 

(e)            Geron will not be entitled to receive any payments under this Section 2 with respect to any payments or reimbursements received by Asterias, any Affiliate of Asterias or any Sales Agent for advertising or similar marketing and promotional expenses.

ARTICLE 3 – REPORTS, RECORDS AND PAYMENTS

3.1                              Reports.  After the First Commercial Sale of a Product, Asterias shall submit to Geron quarterly reports within sixty (60) days after the end of each calendar quarter. Each report shall set forth Product sales by Asterias and each of its Affiliates in the most recently completed calendar quarter, and shall show:

 

  (a)            the gross sales and Net Sales (including all deductions used to calculate Net Sales, and the amounts of each such deduction) during the most recently completed calendar quarter and the royalties, in US dollars, payable with respect thereto;

 

(b)            the amount of each Product sold; and

 

(c)            any amounts due and payable to Asterias during the most recently completed calendar quarter, in US dollars, on account of Products sold by non-Affiliates, where Asterias received a royalty or other cash payment on Product sales; and

 

(d)            the exchange rates used to convert foreign currencies into US dollars.

If no Products have been sold by Asterias and its Affiliates and no royalties or other cash payments have been received by Asterias or its Affiliates with respect to Products sold by non-Affiliates during any reporting period, Asterias shall so report.

3.2                             Records & Audits.

 

(a)            Asterias shall keep, and shall require its Affiliates to keep, accurate and correct records of all Products sold.  Asterias shall also keep accurate and correct records of all royalties received on account of Products sold by non-Affiliates where Asterias receives a royalty or other cash payment on Product sales.  Such records shall be retained by Asterias for at least three (3) years following a given reporting period.

5

(b)            All records described in Section 3.2(a) shall be available during normal business hours for inspection at the expense of Geron by a certified public accountant selected by Geron and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments due. Such inspector shall not disclose to Geron any information other than information relating to the accuracy of reports and payments made under this Agreement, and shall sign a reasonably acceptable confidentiality agreement with Asterias obligating such inspector to retain such information in confidence pursuant to such confidentiality agreement. In the event that any such inspection shows an under reporting and underpayment in excess of five percent (5%) for any twelve-month (12-month) period, then Asterias shall pay the cost of the audit as well as any additional sum that would have been payable to Geron had the Asterias reported correctly, plus an interest charge at a rate of rate per annum 300 basis points over the “prime rate” (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid. Such interest shall be calculated from the date the correct payment was due to Geron up to the date when such payment is actually made by Asterias or an Affiliate. For underpayment not in excess of five percent (5%) for any twelve-month (12-month) period, Asterias shall pay the difference within thirty (30) days without interest charge or inspection cost.

 

(c)            Asterias acknowledges and agrees that, due to the unique nature of the records subject to audit under Section 3.2(b), Geron would be incapable of verifying reports and payments made by Asterias pursuant to this Agreement without access to such records, that there may be no adequate remedy at law for any breach of Asterias’ obligations under Section 3.2(b), and therefore, that upon any breach thereof by Asterias, Geron shall be entitled to seek appropriate equitable relief in addition to whatever remedies it might have at law.

3.3                              Payments.

 

(a)            All royalties due Geron shall be paid in United States dollars.  When Net Sales or royalties are denominated in currencies other than United States dollars, Asterias shall first determine the royalty in the currency of the country in which Products were sold or royalties were paid and then convert the amount into equivalent United States dollars, using the exchange rate published on Bloomberg at 5:00pm California time on the last business day of the applicable period in question or in the Wall Street Journal on such date if not so published on Bloomberg.

 

(b)            Asterias shall pay all payments due hereunder quarterly within sixty (60) calendar days after the end of each calendar quarter. Each such payment shall be for earned payments accrued within Asterias 's most recently completed calendar quarter.

ARTICLE 4– TERM AND TERMINATION

 

This Agreement shall be effective on the Effective Date and shall terminate on the expiration of the Term.  Asterias’ obligation under this Article 4 shall survive termination of this Agreement as follows: (a) with respect to paying royalties and providing reports, until the last required quarterly report has been provided and all royalties due with respect to Net Sales or royalties received by Asterias from non-Affiliates with respect to sales of Products during the Term have been paid; (b) with respect to Geron’s right to audit the books and records of Asterias and its Affiliates, for a period of one year, and (c) with respect to retaining books and records of Product sales and royalties received, for three years.

 

6

ARTICLE 5- CONFIDENTIALITY

5.1            During the Term and for a period of three (3) years thereafter, Geron shall not disclose any Confidential Information to any third party (other than Geron’s Representatives who have a need to know such Confidential Information) or use such Confidential Information to compete with Asterias; provided, however, that this Section 5.1 shall not restrict Geron from performing any obligation or exercising any right under this Agreement and shall not restrict Geron’s individual Representatives from using Residual Knowledge.  For purposes of this Agreement, “Residual Knowledge” means ideas, concepts, know-how, or techniques related to the Confidential Information that are retained in the unaided memories of the Geron’s individual Representatives who have had access to the Confidential Information.  An individual Representative’s memory is considered unaided if the employee has not intentionally memorized the relevant Confidential Information for the purpose of retaining and subsequently using or disclosing it.  Geron shall not direct any of its individual Representatives to use or practice any Residual Knowledge.  In protecting the Confidential Information from unauthorized disclosure to any third party, Geron shall use at least the same degree of care as it uses in preventing the unauthorized disclosure of its own confidential information.

5.2            Notwithstanding anything contained herein to the contrary, Confidential Information shall not include information that: (a) is or becomes publicly available (other than through a breach of this Agreement); (b) was known to or in the possession of Geron or any of its Representatives at the time of disclosure to Geron by any Representative of Asterias or by any Representative of any Affiliate of Asterias; (c) is independently developed or acquired by Geron or any of its Representatives without the use of Confidential Information; (d) is disclosed with the prior written approval of Asterias or any of its Representatives; or (e) becomes known to Geron or its Representatives from a third party  (other than a former officer, director or employee of Geron or its Affiliates who knew such information during the term of their office, directorship or employment with Geron or its Affiliates) on a nonconfidential basis without breach of this Agreement by Geron.

5.3            Notwithstanding anything contained herein to the contrary, Geron shall be permitted to disclose Confidential Information to the extent required by law or pursuant to the order or legal process of a court, administrative agency, or other governmental body (including by deposition, interrogatory, request for documents, subpoena, civil investigation, demand or similar process), or any rule, regulation, policy statement or other formal demand of any national securities exchange, market or automated quotation system; provided, that, to the extent permitted by applicable law or any order or requirement of a court, administrative agency or other governmental body, Geron will, as promptly as practicable, provide Asterias with prior written notice of such requirement so that Asterias may seek a protective or other order at its sole expense, or waive compliance with the terms of this Agreement with respect to such disclosure.  If such protective order is not timely obtained, or if Asterias waives compliance with the provisions hereof or fails to promptly respond to Geron’s written notice, Asterias will, without liability under this Agreement, furnish only that portion of the Confidential Information that it is advised by its outside legal counsel is legally required and will exercise commercially reasonable efforts to obtain assurance that confidential treatment, if available, will be accorded such Confidential Information.  Notwithstanding anything to the contrary contained herein, Geron may disclose Confidential Information to the extent required by federal or state securities laws or reporting obligations to the United States Securities and Exchange Commission.

7

5.4            Except as required by law, including but not limited to federal and state securities laws or reporting obligations to the United States Securities and Exchange Commission, or pursuant to the order or requirement of a court, administrative agency or other governmental body (including by deposition, interrogatory, request for documents, subpoena, civil investigation, demand or similar process), or any rule, regulation, policy statement or other formal demand of any national securities exchange, market or automated quotation system, neither Geron nor Asterias shall publicly disclose any terms and conditions of this Agreement unless expressly authorized to do so in writing by the other party, which authorization shall not be unreasonably withheld.  This restriction shall not apply with respect to any terms and conditions of this Agreement that are or become publicly available (other than through a breach of this Agreement).

5.5            Each of Geron and Asterias acknowledge and agree that due to the unique nature of the Confidential Information and the terms and conditions of this Agreement, there may be no adequate remedy at law for any breach of its obligations under this Article 5, and therefore, that upon any breach thereof by the other party, Geron or Asterias shall be entitled to seek appropriate equitable relief in addition to whatever remedies it might have at law.

ARTICLE 6- NOTICES AND OTHER COMMUNICATIONS

Any notice or other communication required to be given to any party will be deemed to have been properly given and to be effective (a) on the date of delivery if delivered by hand, air courier delivery service, confirmed facsimile transmission, or confirmed electronic mail, or (b) four days after being deposited in the United States Mail, certified first class postage prepaid, in each case if sent to the respective addresses, FAX number or email address given below, or to another address as it shall designate by written notice given to the other party in the manner provided in this Article.

	
 

	
In the case of Asterias:

	
Asterias Biotherapeutics, Inc.

	
 

	
 

	
301 Harbor Bay Parkway, Suite 100

	
 

	
 

	
Alameda, California 94502

	
 

	
 

	
FAX:  (510) 521-3389

	
 

	
 

	
Attention:  Thomas Okarma, Chief Executive Officer

	
 

	
 

	
 

	
 

	
In the case of Geron:

	
Geron Corporation

	
 

	
 

	
149 Commonwealth Drive

	
 

	
 

	
Menlo Park, CA 94024

	
 

	
 

	
FAX:  (650) 473-7750

	
 

	
 

	
Attention:  Vice President, Legal

8

ARTICLE 7 – GOVERNING LAW AND JURISDICTION

7.1            This Agreement and all claims or causes of action (whether in contract or tort or otherwise) based upon, arising out of or related to this Agreement or the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of California without regard to conflict of laws principles that would result in the application of any law other than the laws of the State of California.  Except as provided for in Section 7.2, each of Geron and Asterias: (a) consents to and submits to the exclusive jurisdiction and venue of the Superior Court of the State of California for the  County of Santa Clara of the State of California or the United States District Court for the Northern District of California, in any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement; (b) agrees that all claims in respect of any such Proceeding shall be heard and determined in any such court; (c) shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; and (d) shall not bring any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court.  Each of Geron and Asterias waives any defense of inconvenient forum to the maintenance of any Proceeding so brought and waives any bond, surety or other security that might be required of any other Person with respect thereto.  Each of Geron and Asterias hereby agrees that service of any process, summons, notice or document in accordance with the provisions of Article 6 shall be effective service of process for any Proceeding arising out of or relating to this Agreement or any of the transactions contemplated hereby.  TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT.

7.2            Notwithstanding anything to the contrary contained in this Agreement, any claim (other than a claim for injunctive or other equitable relief from a court of competent jurisdiction in accordance with Section 7.1) for any breach of Geron’s or Asterias’ obligations or covenants under this Agreement (“Claim”) shall be brought and resolved exclusively in accordance with the provisions of Schedule 10.10(b) of the Asset Contribution Agreement and shall otherwise be governed by the applicable provisions of this Article 7 as if Geron or Asterias were bringing such Claim as a Geron Indemnitee or Asterias Indemnitee, respectively, thereunder; provided, however, that nothing in this Section 7.2 shall prevent any party from seeking injunctive and other equitable relief from a court of competent jurisdiction in compliance with Section 7.1 hereof.

7.3            In the event that any party to this Agreement becomes aware of any event or circumstance that would reasonably be expected to constitute or give rise to any Claim for Damages, the party having the right to bring such Claim (“Claimant”) shall take all commercially reasonable efforts to mitigate and minimize all Damages that may result from the breach giving rise to the Claim (it being understood that nothing in this Agreement shall limit such Claimant’s right to seek recovery from the other party with respect to any costs of such mitigation).  Each Claimant shall use reasonable efforts to collect any amounts available under insurance coverage for any Damages for which a Claim may be brought under this Agreement.  The amount of any Damages for which a Claim may be brought shall be net of any amounts recovered by the Claimant under insurance policies with respect to such Damages in excess of the sum of:  (i) reasonable out-of-pocket costs and expenses relating to collection under such policies; and (ii) any deductible associated therewith to the extent paid or by which insurance proceeds were reduced.  “Damages” shall mean any  damage, loss, liability, cost, judgment, award, fee (including any legal fee, expert fee, accounting fee or advisory fee) or expense; provided, however, that in no event shall Damages include any special, indirect, incidental or consequential damages except in the case of a violation of Section 5.1.

9

7.4            Subject to any injunction or other equitable remedies that may be available to any party, a party shall not be liable or responsible in any manner whatsoever to the other party with respect to the matters contemplated by this Agreement other than for Claims brought as provided in this Article 7 and subject to the limitations contained therein; provided, however, that no Claim against a party for fraud by such party shall be subject to the limitations of this Article 7.

ARTICLE 8 ‐ MISCELLANEOUS PROVISIONS

8.1            Nothing herein shall be deemed to constitute either party as the agent or representative of the other party.

8.2            The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the parties hereto.

8.3            The provisions of this Agreement are severable, and in the event that any provisions of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

8.4            The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.

8.5            This Agreement, and the rights and obligations of Asterias under this Agreement, may not be assigned by Asterias except: (a) with the prior written consent of Geron; (b) in connection with a merger or consolidation of Asterias; or (c) an assignment by Asterias in connection with a sale of all or substantially all of the Contributed Patents.  Geron may freely assign this Agreement or any of its rights and obligations under this Agreement; provided, that Geron provides to Asterias a written agreement executed by the assignee agreeing to be bound by all of the terms and conditions of this Agreement in place of the assignor.  Subject to the provisions of this Section 8.5, this Agreement shall inure to the benefit of Geron, Asterias and their respective successors and permitted assigns.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

10

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the Effective Date set forth above.

	
ASTERIAS BIOTHERAPEUTICS, INC.

	
 

	
 

	
 

	
By:

	
s/Thomas Okarma

	
 

	
 

	
Thomas Okarma, Chief Executive Officer

	
 

	
 

 

	
 

	
 

	
GERON CORPORATION

	
 

	
 

	
 

	
 

	
By:

	
s/John Scarlett

	
 

	
 

	
John Scarlett, Chief Executive Officer

	
 

 

[SIGNATURE PAGE TO ROYALTY AGREEMENT]

 

SCHEDULE 1

CONTRIBUTED PATENTS

Notwithstanding anything contained in the Royalty Agreement to the contrary, patents and patent applications marked “(CONSENT REQUIRED)” in this Schedule shall be deemed included on this Schedule and shall be subject to the Royalty Agreement as Contributed Patents only if Geron shall have obtained the prior express written consent of the University of Edinburgh under that certain Research and License Agreement, dated as of May 3, 1999, by and among the Roslin Institute (as predecessor-in-interest to the University of Edinburgh), Geron and Roslin Bio-Med, Ltd. (as predecessor-in-interest to Geron), as amended on October 1, 2002, September 3, 2003 and July 1, 2005, to assign or otherwise transfer such patents and patent applications to Asterias.

 

Geron-Owned Stem Cell Status Report - Active Cases

 

	
 

	
TITLE

	
COUNTRY

	
APPLICATION NUMBER

	
FILING DATE

	
PATENT NUMBER

	
ISSUE DATE

	
STATUS

	
ADDL. ASSIGNEE / JOINT OWNER

	
061/005

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
US

	
09/530,346

	
24-Apr-00

	
6,800,480

	
5-Oct-04

	
Issued

	
 

	
061/006D

	
Feeder-Free Culture Method for Embryonic Stem Cells

	
US

	
10/330,873

	
24-Dec-02

	
7,413,902

	
19-Aug-08

	
Issued

	
 

	
061/235AU

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
AU

	
12771/99

	
23-Oct-98

	
729377

	
17-May-01

	
Issued

	
 

	
061/236CA

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
CA

	
2307807

	
23-Oct-98

	
2,307,807

	
2-Sep-08

	
Issued

	
 

 

	
061/237EP

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
EP

	
98956192.3

	
23-Oct-98

	
 

	
 

	
Pending

	
 

	
061/238JP

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
JP

	
2000-517062

	
23-Oct-98

	
3880795

	
17-Nov-06

	
Issued

	
 

	
061/239JP D

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture

	
JP

	
2000-185486

	
23-Oct-98

	
3880778

	
17-Nov-06

	
Issued

	
 

	
061/241HK

	
Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells

	
HK

	
01100775

	
23-Oct-98

	
 

	
 

	
Pending

	
 

	
081/002C

	
Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer

	
US

	
09/675,321

	
29-Sep-00

	
6,440,735

	
27-Aug-02

	
Issued

	
 

	
081/003P

	
Method for Identifying and Killing Cancer Cells

	
US

	
10/208,243

	
30-Jul-02

	
7,402,307

	
22-Jul-08

	
Issued

	
 

	
081/004D

	
Cellular Telomerase Vaccine and Its Use for Treating Cancer

	
US

	
11/413,838

	
27-Apr-06

	
7,824,849

	
2-Nov-10

	
Issued

	
 

	
081/202CA

	
Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer

	
CA

	
2347067

	
30-Mar-99

	
 

	
 

	
Pending

	
 

2

	
081/206CH

	
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen

	
CH

	
999161938

	
30-Mar-99

	
1068296

	
10-Aug-11

	
Issued

	
 

	
081/207DE

	
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen

	
DE

	
999161938

	
30-Mar-99

	
1068296

	
10-Aug-11

	
Issued

	
 

	
081/208FR

	
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen

	
FR

	
999161938

	
30-Mar-99

	
1068296

	
10-Aug-11

	
Issued

	
 

	
081/209GB

	
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen

	
GB

	
999161938

	
30-Mar-99

	
1068296

	
10-Aug-11

	
Issued

	
 

	
081/210IT

	
Methods and Compositions for Eliciting an Immune Response to a Telomerase Antigen

	
IT

	
999161938

	
30-Mar-99

	
1068296

	
10-Aug-11

	
Issued

	
 

	
090/004D

	
Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells

	
US

	
11/010,230

	
10-Dec-04

	
7,560,281

	
14-Jul-09

	
Issued

	
 

	
090/005C

	
Neural Cell Populations from Primate Pluripotent Stem Cells

	
US

	
12/477,726

	
3-Jun-09

	
8,252,586

	
28-Aug-12

	
Issued

	
 

3

	
090/006C

	
Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells

	
US

	
12/500,998

	
10-Jul-09

	
8,153,428

	
10-Apr-12

	
Issued

	
 

	
090/007C

	
Neural Cell Populations from Primate Pluripotent Stem Cells

	
US

	
13/561,296

	
30-Jul-12

	
 

	
 

	
Pending

	
 

	
091/004

	
cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells

	
US

	
09/688,031

	
10-Oct-00

	
6,667,176

	
23-Dec-03

	
Issued

	
 

	
091/009C

	
Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing

	
US

	
10/039,956

	
23-Oct-01

	
7,041,438

	
9-May-06

	
Issued

	
 

	
091/011P

	
Embryonic Stem Cells Having Genetic Modifications

	
US

	
10/948,956

	
24-Sep-04

	
7,413,904

	
19-Aug-08

	
Issued

	
 

	
091/030P

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
US

	
10/235,094

	
4-Sep-02

	
7,410,798

	
12-Aug-08

	
Issued

	
 

	
091/031D

	
Medium for Growing Human Embryonic Stem Cells

	
US

	
10/873,922

	
21-Jun-04

	
7,297,539

	
20-Nov-07

	
Issued

	
 

	
091/033P

	
Medium for Growing Human Embryonic Stem Cells

	
US

	
10/949,181

	
24-Sep-04

	
7,455,983

	
25-Nov-08

	
Issued

	
 

	
091/037C

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
US

	
12/170,219

	
9-Jul-08

	
 

	
 

	
Pending

	
 

4

	
091/038C

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
US

	
12/710,078

	
22-Feb-10

	
 

	
 

	
Pending

	
 

	
091/039C

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
US

	
12/763,884

	
20-Apr-10

	
8,097,458

	
17-Jan-12

	
Issued

	
 

	
091/040C

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
US

	
13/323,567

	
12-Dec-11

	
 

	
 

	
Pending

	
 

	
091/051

	
Suspension Culture of Human Embryonic Stem Cells

	
US

	
11/917,993

	
18-Dec-07

	
 

	
 

	
Pending

	
 

	
091/201AU

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
AU

	
11128/01

	
10-Jan-01

	
751321

	
5-Dec-02

	
Issued

	
 

	
091/202IL

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
IL

	
141742

	
10-Jan-01

	
141742

	
10-Dec-06

	
Issued

	
 

	
091/204JP D

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
JP

	
2001-138021

	
10-Jan-01

	
4919445

	
10-Feb-12

	
Issued

	
 

	
091/205SG

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
SG

	
200101413-3

	
10-Jan-01

	
79595

	
31-Dec-08

	
Issued

	
 

	
091/206IN

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
IN

	
00361/CHENP/2001

	
10-Jan-01

	
219103

	
25-Apr-08

	
Issued

	
 

5

	
091/207CA

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
CA

	
2388811

	
10-Jan-01

	
2,388,811

	
6-Oct-09

	
Issued

	
 

	
091/209EP

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
EP

	
01900997.6

	
10-Jan-01

	
 

	
 

	
Pending

	
 

	
091/211HK

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
HK

	
03107166

	
10-Jan-01

	
 

	
 

	
Pending

	
 

	
091/212IL D

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
IL

	
177324

	
10-Jan-01

	
177324

	
30-Mar-12

	
Issued

	
 

	
091/217IN D2

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
IN

	
4588/CHENP/2006

	
10-Jan-01

	
238318

	
28-Jan-10

	
Issued

	
 

	
091/218CN D

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
CN

	
200910129670.2

	
10-Jan-01

	
 

	
 

	
Pending

	
 

	
091/219EP D

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
EP

	
10175090.9

	
10-Jan-01

	
 

	
 

	
Pending

	
 

	
091/220HK

	
Techniques for Growth and Differentiation of Human Pluripotent Stem Cells

	
HK

	
11106881.6

	
10-Jan-01

	
 

	
 

	
Pending

	
 

	
091/301AU

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
AU

	
2002323593

	
5-Sep-02

	
2002323593

	
11-Oct-07

	
Issued

	
 

6

	
091/303UK

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
GB

	
0404910.2

	
5-Sep-02

	
2394723

	
20-Jul-05

	
Issued

	
 

	
091/304EP

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
EP

	
02757586.9

	
5-Sep-02

	
 

	
 

	
Pending

	
 

	
091/305IL

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
IL

	
160403

	
5-Sep-02

	
160403

	
17-Sep-10

	
Issued

	
 

	
091/306JP

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
JP

	
2003-525623

	
5-Sep-02

	
 

	
 

	
Pending

	
 

	
091/307SG

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
SG

	
200400924-7

	
5-Sep-02

	
102946

	
31-May-06

	
Issued

	
 

	
091/314EP D

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
EP

	
10174954.7

	
5-Sep-02

	
 

	
 

	
Pending

	
 

	
091/315IL D

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
IL

	
204178

	
5-Sep-02

	
 

	
 

	
Pending

	
 

	
091/316JP D

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
JP

	
2009-271501

	
5-Sep-02

	
 

	
 

	
Pending

	
 

	
091/317HK

	
Culture System for Rapid Expansion of Human Embryonic Stem Cells

	
HK

	
11106437.5

	
5-Sep-02

	
 

	
 

	
Pending

	
 

7

	
091/402EP

	
Medium for Growing Human Embryonic Stem Cells

	
EP

	
05775294.1

	
13-Jul-05

	
 

	
 

	
Pending

	
 

	
091/403AU

	
Medium for Growing Human Embryonic Stem Cells

	
AU

	
2005271723

	
13-Jul-05

	
2005271723

	
31-Mar-11

	
Issued

	
 

	
091/404UK

	
Medium for Growing Human Embryonic Stem Cells

	
GB

	
0702793.1

	
13-Jul-05

	
2431165

	
1-Apr-09

	
Issued

	
 

	
091/405IL

	
Medium for Growing Human Embryonic Stem Cells

	
IL

	
180447

	
13-Jul-05

	
180447

	
1-Feb-12

	
Issued

	
 

	
091/406SG

	
Medium for Growing Human Embryonic Stem Cells

	
SG

	
200700160-5

	
13-Jul-05

	
128950

	
30-Jun-09

	
Issued

	
 

	
091/407HK

	
Medium for Growing Human Embryonic Stem Cells

	
HK

	
07110996.6

	
13-Jul-05

	
1103106

	
17-Jul-09

	
Issued

	
 

	
091/408EP D

	
Medium for Growing Human Embryonic Stem Cells

	
EP

	
10180759.2

	
13-Jul-05

	
 

	
 

	
Pending

	
 

	
091/501AU

	
Suspension Culture of Human Embryonic Stem Cells

	
AU

	
2006262369

	
20-Jun-06

	
2006262369

	
18-Oct-12

	
Issued

	
 

	
091/502CA

	
Suspension Culture of Human Embryonic Stem Cells

	
CA

	
2613369

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/503EP

	
Suspension Culture of Human Embryonic Stem Cells

	
EP

	
06785185.7

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/504GB

	
Suspension Culture of Human Embryonic Stem Cells

	
GB

	
0800365.9

	
20-Jun-06

	
2441488

	
29-Sep-10

	
Issued

	
 

8

	
091/505IL

	
Suspension Culture of Human Embryonic Stem Cells

	
IL

	
188264

	
20-Jun-06

	
188264

	
30-Mar-12

	
Issued

	
 

	
091/506IN

	
Suspension Culture of Human Embryonic Stem Cells

	
IN

	
81/CHENP/2008

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/507JP

	
Suspension Culture of Human Embryonic Stem Cells

	
JP

	
2008-518312

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/508KR

	
Suspension Culture of Human Embryonic Stem Cells

	
KR

	
10-2008-7001755

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/509SG

	
Suspension Culture of Human Embryonic Stem Cells

	
SG

	
200718866-7

	
20-Jun-06

	
138384

	
30-Nov-10

	
Issued

	
 

	
091/510CN

	
Suspension Culture of Human Embryonic Stem Cells

	
CN

	
200680027460.7

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
091/511HK

	
Suspension Culture of Human Embryonic Stem Cells

	
HK

	
08102719.8

	
20-Jun-06

	
1122836

	
26-Nov-10

	
Issued

	
 

	
091/512AU D

	
Suspension Culture of Human Embryonic Stem Cells

	
AU

	
2012203350

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
092/002

	
Conditioned Media for Propagating Human Pluripotent Stem Cells

	
US

	
09/900,752

	
6-Jul-01

	
6,642,048

	
4-Nov-03

	
Issued

	
 

	
093/002

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
US

	
09/718,308

	
20-Nov-00

	
6,458,589

	
1-Oct-02

	
Issued

	
 

9

	
093/003D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
US

	
09/872,182

	
31-May-01

	
6,506,574

	
14-Jan-03

	
Issued

	
 

	
093/004P

	
Process for Making Hepatocytes from Pluripotent Stem Cells

	
US

	
10/001,267

	
31-Oct-01

	
7,256,042

	
14-Aug-07

	
Issued

	
 

	
093/005P

	
Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells

	
US

	
10/087,142

	
1-Mar-02

	
7,282,366

	
16-Oct-07

	
Issued

	
 

	
093/030P

	
Protocols for Making Hepatocytes from Embryonic Stem Cells

	
US

	
10/810,311

	
26-Mar-04

	
7,473,555

	
6-Jan-09

	
Issued

	
 

	
093/032C

	
Protocols for Making Hepatocytes from Embryonic Stem Cells

	
US

	
12/277,136

	
24-Nov-08

	
 

	
 

	
Pending

	
 

	
093/041

	
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells

	
US

	
12/303,104

	
1-Dec-08

	
8,148,151

	
3-Apr-12

	
Issued

	
Univ. Edinburgh

(CONSENT REQUIRED)

	
093/201AU

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
AU

	
2001259170

	
26-Apr-01

	
2001259170

	
11-May-06

	
Issued

	
 

	
093/202CA

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
CA

	
2407505

	
26-Apr-01

	
2,407,505

	
23-Oct-07

	
Issued

	
 

	
093/204EP

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
EP

	
01932661

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/205KR

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
KR

	
2002-7014467

	
26-Apr-01

	
10-0729971

	
13-Jun-07

	
Issued

	
 

10

	
093/206IN

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
IN

	
IN/PCT/2002/01764/CHE

	
26-Apr-01

	
208929

	
16-Aug-07

	
Issued

	
 

	
093/207IL

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
IL

	
152481

	
26-Apr-01

	
152481

	
1-Mar-11

	
Issued

	
 

	
093/208JP

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
JP

	
2001-578620

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/209SG

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
SG

	
200206520-9

	
26-Apr-01

	
92,561

	
31-Mar-05

	
Issued

	
 

	
093/210GB

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
GB

	
0227573.3

	
26-Apr-01

	
2,380,490

	
29-Dec-04

	
Issued

	
 

	
093/211AU D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
AU

	
2004205306

	
26-Apr-01

	
2004205306

	
14-Apr-05

	
Issued

	
 

	
093/211HK

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
HK

	
03108081

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/213CN D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
CN

	
201010528128.7

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/214EP D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
EP

	
010175113.9

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/215KR D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
KR

	
2007-7003241

	
26-Apr-01

	
10-0868473

	
6-Nov-08

	
Issued

	
 

	
093/216IN D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
IN

	
437/CHENP/2007

	
26-Apr-01

	
238673

	
17-Feb-10

	
Issued

	
 

11

	
093/218JP D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
JP

	
2012-139735

	
26-Apr-01

	
 

	
 

	
Pending

	
 

	
093/221AU D

	
Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells

	
AU

	
2004205307

	
26-Apr-01

	
2004205307

	
7-Apr-05

	
Issued

	
 

	
093/401EP

	
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells

	
EP

	
07795625.8

	
1-Jun-07

	
 

	
 

	
Pending

	
Univ. Edinburgh (CONSENT REQUIRED)

	
093/402UK

	
Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells

	
GB

	
0823060.9

	
1-Jun-07

	
2453074

	
22-Jun-11

	
Issued

	
Univ. Edinburgh (CONSENT REQUIRED)

	
094/004D

	
Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells

	
US

	
09/872,183

	
31-May-01

	
6,833,269

	
21-Dec-04

	
Issued

	
 

	
094/005C

	
Neural Progenitor Cell Populations

	
US

	
11/281,040

	
16-Nov-05

	
8,148,148

	
3-Apr-12

	
Issued

	
 

	
094/006C

	
Neural Progenitor Cell Populations

	
US

	
12/332,783

	
11-Dec-08

	
8,252,585

	
28-Aug-12

	
Issued

	
 

	
094/007C

	
Neural Progenitor Cell Populations

	
US

	
13/558,078

	
25-Jul-12

	
 

	
 

	
Pending

	
 

	
094/011P

	
Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells

	
US

	
10/157,288

	
28-May-02

	
7,250,294

	
31-Jul-07

	
Issued

	
 

	
094/013D

	
Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells

	
US

	
11/009,504

	
10-Dec-04

	
7,763,463

	
27-Jul-10

	
Issued

	
 

12

	
094/201IN

	
A Medical Composition Comprising Neural Cells

	
IN

	
397/MAS/2001

	
16-May-01

	
231156

	
3-Mar-09

	
Issued

	
 

	
094/202AU

	
Neural Progenitor Cell Populations

	
AU

	
2001263199

	
16-May-01

	
2001263199

	
16-Sep-04

	
Issued

	
 

	
094/203CA

	
Neural Progenitor Cell Populations

	
CA

	
2409698

	
16-May-01

	
2,409,698

	
26-Oct-10

	
Issued

	
 

	
094/204CN

	
Neural Progenitor Cell Populations

	
CN

	
01809662.X

	
16-May-01

	
100580079

	
13-Jan-10

	
Issued

	
 

	
094/205EP

	
Neural Progenitor Cell Populations

	
EP

	
01937463.6

	
16-May-01

	
 

	
 

	
Pending

	
 

	
094/206IL

	
Neural Progenitor Cell Populations

	
IL

	
152741

	
16-May-01

	
152741

	
1-May-11

	
Issued

	
 

	
094/207JP

	
Neural Progenitor Cell Populations

	
JP

	
2001-585312

	
16-May-01

	
 

	
 

	
Pending

	
 

	
094/208KR

	
Neural Progenitor Cell Populations

	
KR

	
2002-7015192

	
16-May-01

	
903755

	
12-Jun-09

	
Issued

	
 

	
094/209SG

	
Neural Progenitor Cell Populations

	
SG

	
200206677-7

	
16-May-01

	
92,904

	
30-Dec-04

	
Issued

	
 

	
094/210GB

	
Neural Progenitor Cell Populations

	
GB

	
0229369.4

	
16-May-01

	
2,379,447

	
29-Dec-04

	
Issued

	
 

	
094/211HK

	
Neural Progenitor Cell Populations

	
HK

	
03108154.2

	
16-May-01

	
1055765

	
30-Sep-10

	
Issued

	
 

	
094/212JP D

	
Neural Progenitor Cell Populations

	
JP

	
2012-260896

	
16-May-01

	
 

	
 

	
Pending

	
 

	
094/221AU D

	
Neural Progenitor Cell Populations

	
AU

	
2004214542

	
16-May-01

	
2004214542

	
16-Aug-07

	
Issued

	
 

	
094/301AU

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
AU

	
2002322270

	
20-Jun-02

	
2002322270

	
1-Oct-09

	
Issued

	
 

13

	
094/303CN

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
CN

	
02815144.5

	
20-Jun-02

	
100384986

	
30-Apr-08

	
Issued

	
 

	
094/304EP

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
EP

	
02756248.7

	
20-Jun-02

	
 

	
 

	
Pending

	
 

	
094/305GB

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
GB

	
0400167.3

	
20-Jun-02

	
2,393,733

	
14-Sep-05

	
Issued

	
 

	
094/306IN

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
IN

	
2018/CHENP/2003

	
20-Jun-02

	
224902

	
24-Oct-08

	
Issued

	
 

	
094/307IL

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
IL

	
159324

	
20-Jun-02

	
159324

	
31-Jul-12

	
Issued

	
 

	
094/308JP

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
JP

	
2003-507255

	
20-Jun-02

	
4526265

	
11-Jun-10

	
Issued

	
 

	
094/309KR

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
KR

	
2003-7016718

	
20-Jun-02

	
 

	
 

	
Pending

	
 

14

	
094/310SG

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
SG

	
200307601-5

	
20-Jun-02

	
101,708

	
30-Dec-05

	
Issued

	
 

	
094/311HK

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
HK

	
05107808.2

	
20-Jun-02

	
1075673

	
6-Feb-09

	
Issued

	
 

	
094/312CN D

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
CN

	
200610101371.4

	
20-Jun-02

	
101029302

	
30-Mar-11

	
Issued

	
 

	
094/316IN D

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
IN

	
5529/CHENP/2007

	
20-Jun-02

	
247544

	
18-Apr-11

	
Issued

	
 

	
094/318JP D

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
JP

	
2010-009966

	
20-Jun-02

	
 

	
10-Dec-12

	
Issued

	
 

	
094/319JP D2

	
Dopaminergic Neurons and Proliferation-Competent Precursor Cells for Treating Parkinson's Disease

	
JP

	
2012-246396

	
20-Jun-02

	
 

	
 

	
Pending

	
 

15

	
096/003

	
Differentiated Cells Suitable For Human Therapy

	
US

	
09/783,203

	
13-Feb-01

	
6,576,464

	
10-Jun-03

	
Issued

	
 

	
096/004

	
Selective Antibody Targeting of Undifferentiated Stem Cells

	
US

	
09/995,419

	
26-Nov-01

	
6,921,665

	
26-Jul-05

	
Issued

	
Univ. Edinburgh (CONSENT REQUIRED)

	
096/007C

	
Differentiated Cells Suitable For Human Therapy

	
US

	
11/359,341

	
21-Feb-06

	
 

	
 

	
Pending

	
 

	
096/201AU

	
Differentiated Stem Cells Suitable for Human Therapy

	
AU

	
2002237681

	
26-Nov-01

	
2002237681

	
22-Mar-07

	
Issued

	
 

	
096/202CA

	
Differentiated Stem Cells Suitable for Human Therapy

	
CA

	
2434760

	
26-Nov-01

	
 

	
 

	
Pending

	
 

	
096/204EP

	
Differentiated Stem Cells Suitable for Human Therapy

	
EP

	
01986488.3

	
26-Nov-01

	
 

	
 

	
Pending

	
 

	
096/205GB

	
Differentiated Stem Cells Suitable for Human Therapy

	
GB

	
0313389.9

	
26-Nov-01

	
2,386,120

	
9-Mar-05

	
Issued

	
 

	
096/207IL

	
Differentiated Cells Suitable for Human Therapy

	
IL

	
155695

	
26-Nov-01

	
155695

	
1-Feb-08

	
Issued

	
 

	
096/208IN

	
Differentiated Stem Cells Suitable for Human Therapy

	
IN

	
00782/CHENP/2003

	
26-Nov-01

	
229151

	
13-Feb-09

	
Issued

	
 

	
096/211SG

	
Differentiated Stem Cells Suitable for Human Therapy

	
SG

	
200302425-4

	
26-Nov-01

	
96,763

	
31-Jul-06

	
Issued

	
 

	
096/213CN D

	
Differentiated Stem Cells Suitable for Human Therapy

	
CN

	
200910224980.2

	
26-Nov-01

	
 

	
 

	
Pending

	
 

	
096/218IN D

	
A Modified Population of Cells Differentiated from Primate Pluripotent Stem (pPS) Cells

	
IN

	
1873/CHENP/2003

	
26-Nov-01

	
 

	
 

	
Pending

	
 

16

	
096/300GB

	
Selective Antibody Targeting of Undifferentiated Stem Cells

	
GB

	
0128409

	
27-Nov-01

	
2,374,076

	
25-Feb-04

	
Issued

	
Univ. Edinburgh (CONSENT REQUIRED)

	
097/201AU

	
Tolerizing Allografts of Pluripotent Stem Cells

	
AU

	
2002239294

	
21-Nov-01

	
2002239294

	
28-Aug-06

	
Issued

	
 

	
097/205GB

	
Tolerizing Allografts of Pluripotent Stem Cells

	
GB

	
0313387.3

	
21-Nov-01

	
2,386,125

	
23-Feb-05

	
Issued

	
 

	
097/211SG

	
Tolerizing Allografts of Pluripotent Stem Cells

	
SG

	
200302419-7

	
21-Nov-01

	
96,450

	
31-Jul-07

	
Issued

	
 

	
098/201AU

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
AU

	
2002322379

	
3-Jul-02

	
2002322379

	
15-Feb-07

	
Issued

	
 

	
098/202CA

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
CA

	
2453068

	
3-Jul-02

	
 

	
 

	
Pending

	
 

	
098/204EP

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
EP

	
02756367.5

	
3-Jul-02

	
 

	
 

	
Pending

	
 

	
098/205GB

	
Osteoblasts Derived from Human Embryonic Stem Cells

	
GB

	
0400481.8

	
3-Jul-02

	
2,392,674

	
10-Aug-05

	
Issued

	
 

	
098/206IL

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
IL

	
159578

	
3-Jul-02

	
159578

	
1-Mar-11

	
Issued

	
 

	
098/209SG

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
SG

	
200400102

	
3-Jul-02

	
102,198

	
29-Sep-06

	
Issued

	
 

17

	
098/213CN D

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
CN

	
200910152133.X

	
10-Jul-09

	
 

	
 

	
Pending

	
 

	
098/214HK D

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
HK

	
10107815.6

	
3-Jul-02

	
 

	
 

	
Pending

	
 

	
098/217IN D

	
Mesenchymal Cells and Osteoblasts from Human Embryonic Stem Cells

	
IN

	
2634/CHENP/2005

	
3-Jul-02

	
236883

	
25-Nov-09

	
Issued

	
 

	
099/003

	
Cardiomyocyte Precursors from Human Embryonic Stem Cells

	
US

	
10/193,884

	
12-Jul-02

	
7,425,448

	
16-Sep-08

	
Issued

	
 

	
099/004P

	
Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells

	
US

	
10/805,099

	
19-Mar-04

	
7,732,199

	
8-Jun-10

	
Issued

	
 

	
099/006D

	
Differentiation Protocol for Making Human Cardiomyocytes

	
US

	
11/040,691

	
21-Jan-05

	
7,763,464

	
27-Jul-10

	
Issued

	
 

	
099/031

	
Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells

	
US

	
11/086,709

	
21-Mar-05

	
7,452,718

	
18-Nov-08

	
Issued

	
 

	
099/032C

	
Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells

	
US

	
12/210,779

	
15-Sep-08

	
7,897,389

	
1-Mar-11

	
Issued

	
 

	
099/033C

	
Differentiation Protocol for Making Human Cardiomyocytes

	
US

	
12/234,916

	
22-Sep-08

	
7,851,167

	
14-Dec-10

	
Issued

	
 

18

	
099/041

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
US

	
11/471,916

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/201AU

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
AU

	
2002313670

	
12-Jul-02

	
2002313670

	
30-Jul-09

	
Issued

	
 

	
099/202CA

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
CA

	
2453438

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/203CN

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
CN

	
02813927.5

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/204EP

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
EP

	
02753376.9

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/205GB

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
GB

	
0400570.8

	
12-Jul-02

	
2,393,734

	
27-Jul-05

	
Issued

	
 

	
099/206IL

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
IL

	
159580

	
12-Jul-02

	
159,580

	
8-Nov-08

	
Issued

	
 

19

	
099/207IN

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
IN

	
00033/CHENP/2004

	
12-Jul-02

	
250850

	
1-Feb-12

	
Issued

	
 

	
099/208JP

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
JP

	
2003-512669

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/209SG

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
SG

	
200400096-4

	
12-Jul-02

	
101,797

	
27-Jan-06

	
Issued

	
 

	
099/211HK

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
HK

	
05100018.3

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/212KR D

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
KR

	
2010-7000243

	
12-Jul-02

	
10-0073411

	
7-Oct-11

	
Issued

	
 

	
099/214JP D

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
JP

	
2010-219095

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/215IN D

	
Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells

	
IN

	
7542/CHENP/2011

	
12-Jul-02

	
 

	
 

	
Pending

	
 

	
099/301AU

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
AU

	
2005224670

	
18-Mar-05

	
2005224670

	
11-Nov-10

	
Issued

	
 

20

	
099/302CA

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
CA

	
2559854

	
18-Mar-05

	
 

	
 

	
Pending

	
 

	
099/303CN

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
CN

	
200580008779

	
18-Mar-05

	
 

	
 

	
Pending

	
 

	
099/304EP

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
EP

	
05732662.1

	
18-Mar-05

	
 

	
 

	
Pending

	
 

	
099/305GB

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
GB

	
0619719.8

	
18-Mar-05

	
2,427,873

	
10-Sep-08

	
Issued

	
 

	
099/306IL

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
IL

	
178006

	
18-Mar-05

	
178006

	
1-Dec-11

	
Issued

	
 

	
099/307IN

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
IN

	
5842/DELNP/2006

	
18-Mar-05

	
 

	
 

	
Pending

	
 

21

	
099/308JP

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
JP

	
2007-504142

	
18-Mar-05

	
4971131

	
13-Apr-12

	
Issued

	
 

	
099/309SG

	
Method for Making High Purity Cardiomyocyte Preparations Suitable for Regenerative Medicine

	
SG

	
200606477-8

	
18-Mar-05

	
125692

	
31-Mar-09

	
Issued

	
 

	
099/401AU

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
AU

	
2006262329

	
20-Jun-06

	
2006262329

	
7-Apr-11

	
Issued

	
 

	
099/402CA

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
CA

	
2611809

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/403CN

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
CN

	
200680022866.6

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/404EP

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
EP

	
06785229.3

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/405GB

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
GB

	
0800264.4

	
20-Jun-06

	
2441718

	
6-Oct-10

	
Issued

	
 

	
099/406IL

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
IL

	
187611

	
20-Jun-06

	
 

	
 

	
Allowed

	
 

22

	
099/407IN

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
IN

	
9175/DELNP/2007

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/408JP

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
JP

	
2008-518339

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/409KR

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
KR

	
10-2008-7001452

	
20-Jun-06

	
 

	
 

	
Pending

	
 

	
099/410SG

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
SG

	
200718867-5

	
20-Jun-06

	
138693

	
30-Nov-10

	
Issued

	
 

	
099/411HK

	
Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

	
HK

	
08103905

	
20-Jun-06

	
1109913

	
3-Dec-10

	
Issued

	
 

	
131/011P

	
Using Undifferentiated Embryonic Stem Cells to Control the Immune System

	
US

	
10/949,702

	
24-Sep-04

	
7,799,324

	
21-Sep-10

	
Issued

	
Univ. Western Ontario

	
131/201AU

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
AU

	
2002366603

	
6-Dec-02

	
2002366603

	
15-Jan-09

	
Issued

	
Univ. Western Ontario

	
131/204EP

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
EP

	
02804740.5

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/205GB

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
GB

	
0414957.1

	
6-Dec-02

	
2399572

	
7-Jun-06

	
Issued

	
Univ. Western Ontario

23

	
131/206IL

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
IL

	
162130

	
6-Dec-02

	
162130

	
1-Sep-10

	
Issued

	
Univ. Western Ontario

	
131/208JP

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
JP

	
2003-551273

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/210SG

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
SG

	
200403341-1

	
6-Dec-02

	
104768

	
31-Jul-06

	
Issued

	
Univ. Western Ontario

	
131/212AU D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
AU

	
2008243182

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/213CN D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
CN

	
200910174800.4

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/214EP D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
EP

	
10175120.4

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/215GB D

	
Use of Undifferentiated Embryonic Stem Cells To Induce Immune Tolerance and Improve Allograft Acceptance

	
GB

	
0503865.8

	
6-Dec-02

	
2412379

	
29-Mar-06

	
Issued

	
Univ. Western Ontario

	
131/216IL D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
IL

	
200768

	
6-Dec-02

	
200768

	
1-Feb-12

	
Issued

	
Univ. Western Ontario

	
131/217KR D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
KR

	
2010-7024253

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/218JP D

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
JP

	
2009-265829

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

24

	
131/219HK

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
HK

	
11109490.3

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
131/220AU D2

	
Hematopoietic Cells from Human Embryonic Stem Cells

	
AU

	
 

	
6-Dec-02

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
132/002

	
Islet Cells from Human Embryonic Stem Cells

	
US

	
10/313,739

	
6-Dec-02

	
7,033,831

	
25-Apr-06

	
Issued

	
 

	
132/003D

	
Endoderm Cells from Human Embryonic Stem Cells

	
US

	
11/262,633

	
31-Oct-05

	
7,326,572

	
5-Feb-08

	
Issued

	
 

	
132/004C

	
Islet Cells from Human Embryonic Stem Cells

	
US

	
11/960,477

	
19-Dec-07

	
 

	
 

	
Pending

	
 

	
132/005C

	
Islet Cells from Human Embryonic Stem Cells

	
US

	
12/262,536

	
31-Oct-08

	
 

	
 

	
Pending

	
 

	
132/006C

	
Islet Cells from Human Embryonic Stem Cells

	
US

	
12/543,875

	
19-Aug-09

	
 

	
 

	
Pending

	
 

	
132/007C

	
Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells

	
US

	
12/762,676

	
19-Apr-10

	
 

	
 

	
Pending

	
 

	
132/008C

	
Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells

	
US

	
12/947,605

	
16-Nov-10

	
 

	
 

	
Pending

	
 

	
132/031

	
Differentiation and Enrichment of Islet-Like Cells from Human Pluripotent Stem Cells

	
US

	
12/303,895

	
8-Dec-08

	
 

	
 

	
Allowed

	
 

25

	
132/201AU

	
Islet Cells from Human Embryonic Stem Cells

	
AU

	
2002364143

	
6-Dec-02

	
2002364143

	
5-Jun-08

	
Issued

	
 

	
132/202CA

	
Islet Cells from Human Embryonic Stem Cells

	
CA

	
2470539

	
6-Dec-02

	
2,470,539

	
4-Oct-11

	
Issued

	
 

	
132/203CN

	
Islet Cells from Human Embryonic Stem Cells

	
CN

	
02824367.6

	
6-Dec-02

	
1602351

	
30-Mar-11

	
Issued

	
 

	
132/204EP

	
Islet Cells from Human Embryonic Stem Cells

	
EP

	
02799217.1

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/205GB

	
Islet Cells from Human Embryonic Stem Cells

	
GB

	
0414958.9

	
6-Dec-02

	
2,399,823

	
15-Feb-06

	
Issued

	
 

	
132/206IL

	
Islet Cells from Human Embryonic Stem Cells

	
IL

	
162131

	
6-Dec-02

	
162131

	
31-Mar-11

	
Issued

	
 

	
132/207IN

	
Islet Cells from Human Embryonic Stem Cells

	
IN

	
1795/DELNP/2004

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/208JP

	
Islet Cells from Human Embryonic Stem Cells

	
JP

	
2003-551271

	
6-Dec-02

	
4666567

	
21-Jan-11

	
Issued

	
 

	
132/209KR

	
Islet Cells from Human Embryonic Stem Cells

	
KR

	
2004-7008713

	
6-Dec-02

	
1089591

	
29-Nov-11

	
Issued

	
 

	
132/210SG

	
Islet Cells from Human Embryonic Stem Cells

	
SG

	
200403559-8

	
6-Dec-02

	
104,854

	
31-Aug-06

	
Issued

	
 

	
132/211GB D

	
Islet Cells from Human Embryonic Stem Cells

	
GB

	
0517624.3

	
6-Dec-02

	
2415432

	
6-Sep-06

	
Issued

	
 

	
132/212HK

	
Islet Cells from Human Embryonic Stem Cells

	
HK

	
05106662.9

	
6-Dec-02

	
1074218

	
2-Dec-11

	
Issued

	
 

	
132/213CN D

	
Islet Cells from Human Embryonic Stem Cells

	
CN

	
200710307353.6

	
6-Dec-02

	
 

	
 

	
Pending

	
 

26

	
132/214HK

	
Islet Cells from Human Embryonic Stem Cells

	
HK

	
09100086.6

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/215AU D

	
Islet Cells from Human Embryonic Stem Cells

	
AU

	
2007254644

	
6-Dec-02

	
2007254644

	
22-Apr-10

	
Issued

	
 

	
132/216IL D

	
Islet Cells from Human Embryonic Stem Cells

	
IL

	
188472

	
6-Dec-02

	
188472

	
31-Mar-11

	
Issued

	
 

	
132/217IN D

	
Islet Cells from Human Embryonic Stem Cells

	
IN

	
6576/DELNP/2009

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/218JP D

	
Islet Cells from Human Embryonic Stem Cells

	
JP

	
2008-040781

	
6-Dec-02

	
4917559

	
3-Feb-12

	
Issued

	
 

	
132/219KR D

	
Islet Cells from Human Embryonic Stem Cells

	
KR

	
2008-7002476

	
6-Dec-02

	
10-0008868

	
11-Jan-11

	
Issued

	
 

	
132/220AU D2

	
Islet Cells from Human Embryonic Stem Cells

	
AU

	
2010200610

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/221CA D

	
Islet Cells from Human Embryonic Stem Cells

	
CA

	
2692325

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/222EP D

	
Islet Cells from Human Embryonic Stem Cells

	
EP

	
10174969.5

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/223HK

	
Islet Cells from Human Embryonic Stem Cells

	
HK

	
11106412.4

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/224JP D2

	
Islet Cells from Human Embryonic Stem Cells

	
JP

	
2011-258931

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
132/225KR D2

	
Islet Cells from Human Embryonic Stem Cells

	
KR

	
 

	
 

	
 

	
 

	
Unfiled

	
 

	
133/003C

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
US

	
11/345,878

	
1-Feb-06

	
7,906,330

	
15-Mar-11

	
Issued

	
 

27

	
133/004C

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
US

	
13/021,497

	
4-Feb-11

	
 

	
 

	
Pending

	
 

	
133/201AU

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
AU

	
2002366602

	
6-Dec-02

	
2002366602

	
16-Oct-08

	
Issued

	
 

	
133/204EP

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
EP

	
02804739.7

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
133/206IL

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
IL

	
162132

	
6-Dec-02

	
162132

	
29-Jun-10

	
Issued

	
 

	
133/207IN

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
IN

	
1794/DELNP/2004

	
6-Dec-02

	
 

	
 

	
Pending

	
 

	
133/209KR

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
KR

	
2004-7008714

	
6-Dec-02

	
10-0973453

	
27-Jul-10

	
Issued

	
 

	
133/210SG

	
Chondrocyte Precursors Derived from Human Embryonic Stem Cells

	
SG

	
200403261-1

	
6-Dec-02

	
105,123

	
31-Aug-06

	
Issued

	
 

	
135/002

	
A Marker System for Preparing and Characterizing High-Quality Human Embryonic Stem Cells

	
US

	
10/389,431

	
13-Mar-03

	
7,153,650

	
26-Dec-06

	
Issued

	
 

28

	
135/201EP

	
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells

	
EP

	
04757690.5

	
13-Mar-04

	
 

	
 

	
Pending

	
 

	
135/202SG

	
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells

	
SG

	
200505876-3

	
13-Mar-04

	
115,079

	
31-Oct-07

	
Issued

	
 

	
135/203GB

	
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells

	
GB

	
0520847.5

	
13-Mar-04

	
2415781

	
18-Jul-07

	
Issued

	
 

	
135/212SG D

	
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells

	
SG

	
200708419-7

	
13-Mar-04

	
151119

	
29-May-09

	
Issued

	
 

	
135/213GB D

	
Genes That Are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells

	
GB

	
0708707.5

	
13-Mar-04

	
2434867

	
7-Nov-07

	
Issued

	
 

	
138/202GB

	
Dendritic Cell Vaccines Made from Embryonic Stem Cells for Treating Cancer

	
GB

	
0703122.2

	
10-Aug-05

	
2431582

	
23-Dec-09

	
Issued

	
 

	
138/204HK

	
Dendritic Cell Vaccines for Treating Cancer Made from Embryonic Stem Cells

	
HK

	
07110697.8

	
10-Aug-05

	
1105429

	
23-Apr-10

	
Issued

	
 

	
151/003

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
US

	
12/412,183

	
26-Mar-09

	
8,093,049

	
10-Jan-12

	
Issued

	
 

29

	
151/004C

	
Systems for Differentiating Pluripotent Stem Cells into Hematopoietic Lineage Cells

	
US

	
13/312,349

	
6-Dec-11

	
 

	
 

	
Pending

	
 

	
151/201AU

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
AU

	
2009228215

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/202CA

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
CA

	
2718438

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/203CN

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
CN

	
200980116566.8

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/204EP

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
EP

	
09724052.7

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/206IL

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
IL

	
208116

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/207IN

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
IN

	
6087/CHENP/2010

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/208JP

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
JP

	
2011-502069

	
26-Mar-09

	
 

	
 

	
Pending

	
 

30

	
151/209KR

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
KR

	
2010-7021271

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/210SG

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
SG

	
201006607-4

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
151/211HK

	
Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells

	
HK

	
11105528.7

	
26-Mar-09

	
 

	
 

	
Pending

	
 

	
161/002

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
US

	
12/362,190

	
29-Jan-09

	
8,241,907

	
14-Aug-12

	
Issued

	
 

	
161/003C

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
US

	
13/546,381

	
11-Jul-12

	
 

	
 

	
Pending

	
 

	
161/201AU

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
AU

	
2009209157

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/202CA

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
CA

	
2712891

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/203CN

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
CN

	
200980103922.2

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/204EP

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
EP

	
09705923.2

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/205IL

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
IL

	
207083

	
29-Jan-09

	
 

	
 

	
Pending

	
 

31

	
161/206IN

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
IN

	
5135/CHENP/2010

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/207JP

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
JP

	
2010-545155

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/208KR

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
KR

	
2010-7019066

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/209SG

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
SG

	
201005466-6

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
161/210HK

	
Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes

	
HK

	
11106743.4

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/002

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
US

	
12/362,250

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/201AU

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
AU

	
2009209167

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/202CA

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
CA

	
2714010

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/203CN

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
CN

	
200980103921.8

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/204EP

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
EP

	
09705909.1

	
29-Jan-09

	
 

	
 

	
Pending

	
 

32

	
162/205IL

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
IL

	
207085

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/206IN

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
IN

	
5136/CHENP/2010

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/207JP

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
JP

	
2010-545160

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/208KR

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
KR

	
2010-7019153

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/209SG

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
SG

	
201005462-5

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
162/210HK

	
Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells

	
HK

	
11102599.8

	
29-Jan-09

	
 

	
 

	
Pending

	
 

	
164/003C

	
Synthetic Surfaces for Differentiating Stem Cells into Cardiomyocytes (amended)

	
US

	
12/701,731

	
8-Feb-10

	
 

	
 

	
Pending

	
 

	
165/002

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
US

	
12/823,739

	
25-Jun-10

	
8,323,966

	
4-Dec-12

	
Issued

	
 

33

	
165/003C

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
US

	
13/679,663

	
16-Nov-12

	
 

	
 

	
Pending

	
 

	
165/201AU

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
AU

	
2010266016

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/202CA

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
CA

	
2766164

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/203CN

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
CN

	
201080032011.8

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/204IL

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
IL

	
217061

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/205IN

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
IN

	
47/CHENP/2012

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/206JP

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
JP

	
2012-517776

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/207KR

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
KR

	
2012-7001572

	
25-Jun-10

	
 

	
 

	
Pending

	
 

34

	
165/208SG

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
SG

	
201109522-1

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/209GB

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
GB

	
1201047.6

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
165/210EP

	
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes

	
EP

	
10792733.7

	
25-Jun-10

	
 

	
 

	
Pending

	
 

	
166/200PCT

	
Enriched Populations of Cardiomyocyte Lineage Cells from Pluripotent Stem Cells

	
WO

	
PCT/US2012/30799

	
28-Mar-12

	
 

	
 

	
Pending

	
 

Geron-Licensed Stem Cell Status Report - Active Cases

	
FILE NO.

	
TITLE

	
COUNTRY

	
APPLICATION NUMBER

	
FILING DATE

	
PATENT NUMBER

	
ISSUE DATE

	
STATUS

	
ASSIGNEE

	
131/004C

	
Reconstructing Hematopoietic Cell Function Using Human Embryonic Stem Cells

	
US

	
10/862,625

	
7-Jun-04

	
 

	
 

	
Pending

	
Univ. Western Ontario

	
134/002

	
Method of Producing Oligodendrocytes from Human Embryonic Stem Cells for Drug Screening or Treatment of Spinal Cord Injury

	
US

	
10/406,817

	
4-Apr-03

	
7,285,415

	
23-Oct-07

	
Issued

	
Regents Univ. California

35

	
134/004C

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
US

	
11/637,632

	
11-Dec-06

	
7,579,188

	
25-Aug-09

	
Issued

	
Regents Univ. California

	
134/005D

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
US

	
12/357,244

	
21-Jan-09

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/201AU

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
AU

	
2003250477

	
11-Jul-03

	
2003250477

	
3-Jul-08

	
Issued

	
Regents Univ. California

	
134/202CA

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
CA

	
2489203

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/203CN

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
CN

	
03816184.2

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/204EP

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
EP

	
03764084.4

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

36

	
134/205GB

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
GB

	
0502774.3

	
11-Jul-03

	
2,407,822

	
22-Feb-06

	
Issued

	
Regents Univ. California

	
134/206IL

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
IL

	
165645

	
11-Jul-03

	
165645

	
1-Mar-11

	
Issued

	
Regents Univ. California

	
134/207IN

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
IN

	
4091/DELNP/2004

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/208JP

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
JP

	
2005-505090

	
11-Jul-03

	
4823689

	
24-Nov-11

	
Issued

	
Regents Univ. California

	
134/209SG

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
SG

	
200407816-8

	
11-Jul-03

	
108,775

	
31-Jan-07

	
Issued

	
Regents Univ. California

37

	
134/210HK

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
HK

	
06113936.4

	
19-Dec-06

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/211EP D

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
EP

	
10175854.8

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/212JP D

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
JP

	
2011-047716

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/213IN D

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
IN

	
4057/DELNP/2011

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
134/214HK

	
Oligodendrocytes Derived from Human Embryonic Stem Cells for Remyelination and Treatment of Spinal Cord Injury

	
HK

	
11105339.6

	
11-Jul-03

	
 

	
 

	
Pending

	
Regents Univ. California

	
136/002

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
US

	
13/082,727

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/201AU

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
AU

	
 

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

38

	
136/202CA

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
CA

	
 

	
8-Apr-11

	
 

	
 

	
Unfiled

	
Univ. Edinburgh

	
136/203CN

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
CN

	
 

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/204EP

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
EP

	
11718764.1

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/205IN

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
IN

	
9325/CHENP/2012

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/206IL

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
IL

	
222292

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/207JP

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
JP

	
 

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
136/208SG

	
Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof

	
SG

	
201207371-4

	
8-Apr-11

	
 

	
 

	
Pending

	
Univ. Edinburgh

	
150/001C

	
Method for Producing Dendritic Cells

	
US

	
09/849,499

	
4-May-01

	
7,247,480

	
24-Jul-07

	
Issued

	
Isis Innovation, Ltd.

	
150/003C

	
Method for Producing Dendritic Cells

	
US

	
11/789,669

	
24-Apr-07

	
7,473,556

	
6-Jan-09

	
Issued

	
Isis Innovation, Ltd.

39

	
150/004C

	
Method for Producing Dendritic Cells

	
US

	
12/326,831

	
2-Dec-08

	
7,781,213

	
24-Aug-10

	
Issued

	
Isis Innovation, Ltd.

	
150/005C

	
Method for Producing Dendritic Cells

	
US

	
12/841,064

	
21-Jul-10

	
8,232,100

	
31-Jul-12

	
Issued

	
Isis Innovation, Ltd.

	
150/006C

	
Method for Producing Dendritic Cells

	
US

	
13/538,995

	
29-Jun-12

	
 

	
 

	
Pending

	
Isis Innovation, Ltd.

	
150/201AU

	
Method for Producing Dendritic Cells

	
AU

	
200010584

	
5-Nov-99

	
768,267

	
4-Dec-03

	
Issued

	
Isis Innovation, Ltd.

	
150/202CA

	
Dendritic Cell Manipulation

	
CA

	
2350210

	
5-Nov-99

	
 

	
 

	
Pending

	
Isis Innovation, Ltd.

	
150/203EP

	
Method for Producing Dendritic Cells

	
EP

	
99954148.5

	
5-Nov-99

	
 

	
 

	
Pending

	
Isis Innovation, Ltd.

	
600/001

	
Lysosomal Targeting of Immunogens

	
US

	
08/006,845

	
22-Jan-93

	
5,633,234

	
27-May-97

	
Issued

	
Johns Hopkins Univ.

	
600/201CA

	
Lysosomal Targeting of Immunogens

	
CA

	
2154445

	
21-Jan-94

	
2,154,445

	
26-Jun-07

	
Issued

	
Johns Hopkins Univ.

	
600/203JP

	
Lysosomal Targeting of Immunogens

	
JP

	
19940517149

	
21-Jan-94

	
3581366

	
30-Jul-04

	
Issued

	
Johns Hopkins Univ.

	
600/204AT

	
Lysosomal Targeting of Immunogens

	
AT

	
94910648.8

	
21-Jan-94

	
180835

	
15-Jun-99

	
Issued

	
Johns Hopkins Univ.

	
600/205DE

	
Lysosomal Targeting of Immunogens

	
DE

	
94910648.8

	
21-Jan-94

	
69418856

	
20-Jan-00

	
Issued

	
Johns Hopkins Univ.

	
600/206DK

	
Lysosomal Targeting of Immunogens

	
DK

	
94910648.8

	
21-Jan-94

	
680513

	
27-Dec-99

	
Issued

	
Johns Hopkins Univ.

	
600/207ES

	
Lysosomal Targeting of Immunogens

	
ES

	
94910648.8

	
21-Jan-94

	
2132395

	
16-Aug-99

	
Issued

	
Johns Hopkins Univ.

	
600/208GR

	
Lysosomal Targeting of Immunogens

	
GR

	
94910648.8

	
21-Jan-94

	
3031026

	
31-Dec-99

	
Issued

	
Johns Hopkins Univ.

	
601/201EP

	
Chimeric Vaccines

	
EP

	
02763958.2

	
5-Apr-02

	
 

	
 

	
Pending

	
Johns Hopkins Univ.

	
601/202CA

	
Chimeric Vaccines

	
CA

	
2446462

	
4-May-02

	
 

	
 

	
Pending

	
Johns Hopkins Univ.

	
800/001

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
08/640,444

	
30-Apr-96

	
5,853,719

	
29-Dec-98

	
Issued

	
Duke Univ.

40

	
800/002C

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
09/073,819

	
6-May-98

	
6,306,388

	
23-Oct-01

	
Issued

	
Duke Univ.

	
800/003C

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
09/875,264

	
7-Jun-01

	
7,101,705

	
5-Sep-06

	
Issued

	
Duke Univ.

	
800/010P

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
09/171,916

	
16-Feb-99

	
7,105,157

	
12-Sep-06

	
Issued

	
Duke Univ.

	
800/011D

	
RNA-loaded Antigen Presenting Cells

	
US

	
09/667,319

	
22-Sep-00

	
6,670,186

	
30-Dec-03

	
Issued

	
Duke Univ.

	
800/012C

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
11/250,546

	
17-Oct-05

	
7,601,343

	
13-Oct-09

	
Issued

	
Duke Univ.

	
800/013D

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
12/585,028

	
1-Sep-09

	
8,263,066

	
11-Sep-12

	
Issued

	
Duke Univ.

	
800/014C

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
US

	
13/554,938

	
20-Jul-12

	
 

	
 

	
Pending

	
Duke Univ.

	
800/020P

	
Method of Identifying Tumor Antigens that Elicit a T-cell Response

	
US

	
09/302,329

	
30-Apr-99

	
6,387,701

	
14-May-02

	
Issued

	
Duke Univ.

41

	
800/201AU

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
AU

	
1997/28213

	
30-Apr-97

	
724267

	
11-Jan-01

	
Issued

	
Duke Univ.

	
800/202CA

	
Compositions and Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
CA

	
2253632

	
30-Apr-97

	
2,253,632

	
16-Dec-08

	
Issued

	
Duke Univ.

	
800/204JP

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
JP

	
539210/97

	
30-Apr-97

	
3836151

	
4-Aug-06

	
Issued

	
Duke Univ.

	
800/213EP D

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
EP

	
06015438.2

	
30-Apr-97

	
 

	
 

	
Pending

	
Duke Univ.

	
800/214JP D

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
JP

	
2006-129005

	
30-Apr-97

	
3955311

	
11-May-07

	
Issued

	
Duke Univ.

	
800/216HK

	
Methods for Treating Cancers and Pathogen Infections Using Antigen-presenting Cells Loaded with RNA

	
HK

	
11108880.3

	
30-Apr-97

	
 

	
 

	
Pending

	
Duke Univ.

	
811/002

	
In Situ Maturation of Dendritic Cells

	
US

	
10/536,211

	
10-Dec-03

	
7,785,583

	
31-Aug-10

	
Issued

	
Duke Univ.

	
811/201AU

	
In Situ Maturation of Dendritic Cells

	
AU

	
2003296439

	
10-Dec-03

	
2003296439

	
10-Jul-09

	
Issued

	
Duke Univ.

42

	
821/001

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
US

	
10/362,715

	
24-Feb-03

	
 

	
 

	
Allowed

	
Gerold Schuler

	
821/002C

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
US

	
13/479,612

	
24-May-12

	
 

	
 

	
Pending

	
Gerold Schuler

	
821/206JP

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
JP

	
522234/02

	
24-Aug-01

	
4610847

	
22-Oct-10

	
Issued

	
Gerold Schuler

	
821/215AT

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
AT

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/216BE

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
BE

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/217DK

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
DK

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/218FR

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
FR

	
 

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

43

	
821/219IT

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
IT

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/220NL

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
NL

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/221SE

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
SE

	
19607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
821/222UK

	
Method for Producing Ready to Use, Antigen Loaded or Unloaded, Cryoconserved Mature Dendritic Cells

	
GB

	
019607084

	
24-Aug-01

	
1311658

	
15-Oct-08

	
Issued

	
Gerold Schuler

	
822/002C

	
CD4+ CD25+ Regulatory T Cells from Human Blood

	
US

	
13/530,488

	
22-Jun-12

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

	
822/201AU

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
AU

	
2002257648

	
12-Mar-02

	
2,002,257,648

	
17-Jan-08

	
Issued

	
Argos Therapeutics, Inc.

	
822/202BR

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
BR

	
0208076.1

	
12-Mar-02

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

	
822/203CA

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
CA

	
2441213

	
12-Mar-02

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

44

	
822/204CN

	
CD4+ CD25+ Regulatory T Cells from Human Blood

	
CN

	
02809777.7

	
12-Mar-02

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

	
822/206JP

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
JP

	
571855/02

	
12-Mar-02

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

	
822/207KR

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
KR

	
2003-7011970

	
12-Mar-02

	
 

	
 

	
Pending

	
Argos Therapeutics, Inc.

	
822/208DE

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
DE

	
 

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
822/209FR

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
FR

	
027273978

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
822/210IE

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
IE

	
027273978

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
822/211NL

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
NL

	
027273978

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
822/212SE

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
SE

	
027273978

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
822/213UK

	
CD4+CD25+ Regulatory T Cells from Human Blood

	
GB

	
027273978

	
12-Mar-02

	
1379625

	
30-Jun-10

	
Issued

	
Argos Therapeutics, Inc.

	
830/004C

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
US

	
08/458,230

	
2-Jun-95

	
5,851,756

	
22-Dec-98

	
Issued

	
Rockefeller Univ. and Argos

	
830/005D

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
US

	
09/073,596

	
6-May-98

	
 

	
 

	
Pending

	
Rockefeller Univ. and Argos

45

	
830/010P

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
US

	
08/261,537

	
17-Jun-94

	
5,994,126

	
30-Nov-99

	
Issued

	
Rockefeller Univ. and Argos

	
830/201AU

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
AU

	
40461/93

	
1-Apr-93

	
687733

	
5-Mar-98

	
Issued

	
Rockefeller Univ. and Argos

	
830/202CA

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
CA

	
2133409

	
1-Apr-93

	
2,133,409

	
24-May-11

	
Issued

	
Rockefeller Univ. and Argos

	
830/204JP

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
JP

	
517738/1993

	
1-Apr-93

	
3649335

	
18-May-05

	
Issued

	
Rockefeller Univ. and Argos

	
830/312MN

	
Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens

	
MN

	
93911581.2

	
1-Apr-93

	
633,929

	
3-Mar-04

	
Issued

	
Rockefeller Univ. and Argos

 

 

46

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]